Sotera Health Co - Willowbrook Group Settlement Term Sheet

EX-10.46 16 shc20221231_exhibitx10x46.htm EX-10.46 Sotera Health Co - Willowbrook Group Settlement Term Sheet

Exhibit 10.46

[Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K and marked with asterisks. The omitted information is (i) not material and (ii) the type that the registrant treats as private or confidential.]

Willowbrook: Group Settlement Term Sheet

Pursuant to this binding short form Term Sheet (“Term Sheet”), the Parties agree to the following terms in full and final resolution of the Covered Claims:

1.Documentation.

a.The parties intend this to be a binding Term Sheet, and that it will become binding once it has been executed by an authorized representative from each member of the PEC, as well as by counsel for Sotera Health Company, Sotera Health LLC and Sterigenics U.S., LLC.

b.An authorized representative from each PEC law firm must sign and agree to the terms reflected in the Term Sheet by no later than Monday, January 9, 2023.

c.The Parties signing below (“Parties”) agree to work in good faith to draft and execute a full settlement agreement in accordance with this Term Sheet (“Settlement Agreement” or “Willowbrook Group Settlement Agreement”). The Settlement Agreement is subject to the approval of all of the Parties. The failure to execute a full Settlement Agreement does not impact the binding effect of this Term Sheet.

d.Settling Defendants (as defined below) expressly deny any and all liability. Nothing in this Term Sheet, including the qualified settlement fund amount, is an admission of any alleged fact, liability or fault, or that the use and/or emission of ethylene oxide by and/or from Sterigenics US’s operations in or around Willowbrook, Illinois has ever caused or created safety hazards or health risks of any sort to the surrounding community.

2.Definitions.

a.The word “Plaintiffs” refers to all persons who are plaintiffs with a Covered Claim as of the date this Term Sheet is signed, and includes any additional persons who have become plaintiffs at the time the Settlement Agreement is signed, but does not include those listed on Appendix C. The list of Plaintiffs covered by this Term Sheet is set forth in Appendix A to this Term Sheet, and will be updated by PEC to include any additional persons who have become plaintiffs at the time the Settlement Agreement is signed.

b.The phrase “Clients with Unfiled Claims” refers to individuals who have retained Plaintiffs’ Counsel in connection with a Covered Claim as of the date this Term Sheet is signed, but who have not filed a lawsuit against any of the Released Parties. “Clients with Unfiled Claims” includes any additional individuals who retain Plaintiffs’ Counsel in connection with a Covered Claim after the signing of the Term Sheet and have not yet filed a lawsuit against any of the Released Parties at the time the Settlement Agreement is signed. The list of Clients with Unfiled Claims is set forth in Appendix B to this Term Sheet, and will be updated by PEC to include any additional “Clients with Unfiled Claims” at the time the Settlement Agreement is signed. PEC will in good faith work to finalize retention by any and all potential clients and supplement Appendices A and B accordingly, by the date the Settlement Agreement is signed.

c.The term “PEC” refers to the Plaintiffs’ Executive Committee, which is composed of the following firms: Salvi, Schostock & Pritchard, PC; Romanucci & Blandon, LLC; Hart McLaughlin & Eldridge, LLC; The Collins Law Firm, PC; Smith LaCien, LLP; Tomasik Kotin Kasserman, LLC and Miner Barnhill & Galland, PC.

d.The term “Non-PEC Firms” refers to any and all law firms representing Eligible Claimants that are not members of the PEC.

e.The phrase “Plaintiffs’ Counsel” refers to the law firms representing Eligible Claimants, including the PEC and Non-PEC Firms; a list of those law firms is set forth in Appendix D to this Term Sheet. PEC have represented that they are negotiating this Term Sheet on behalf of Plaintiffs’ Counsel and each of their clients who is a specific Eligible Claimant and is identified in Appendices A and B.

f.“Sotera Health” refers to Sotera Health Company, Sotera Health Holdings, LLC, Sotera Health LLC, Sotera Health Topco Parent, LP, and Sotera Health GP, LLC.

g.“Sterigenics US” refers to Sterigenics U.S., LLC and all of its predecessor and successor entities.

h.“GTCR” refers to GTCR LLC, GTCR L.L.C., and GTCR Golder Rauner II, L.L.C.; all funds associated with GTCR LLC, GTCR L.L.C., and GTCR Golder Rauner II, L.L.C., including without limitation GTCR Fund IX/A, L.P., GTCR Fund IX/B, L.P., GTCR Co-Invest III, L.P., GTCR Fund XI/A LP, GTCR Fund XI/CLP, GTCR Partners XI/A&C LP, GTCR Co-Invest XI LP, GTCR Investment XI LLC, GTCR Fund XI/A VCOC, GTCR Fund XI/C VCOC; and the respective affiliates, managers, limited partners, and members of (i) GTCR LLC, GTCR L.L.C., GTCR Golder Rauner II, L.L.C., and (ii) the funds associated with GTCR LLC, GTCR L.L.C., and GTCR Golder Rauner II, L.L.C.

i.“Warburg Pincus” refers to Warburg Pincus LLC and all funds, general partners and management companies associated with or managed by Warburg Pincus LLC or its affiliates, including without limitation Warburg Pincus Private Equity XI, LP, Warburg Pincus Private Equity XI-B, LP, Warburg Pincus Private Equity XI-C, LP, Warburg Pincus XI Partners, LP, WP XI Partners, LP, Warburg Pincus XI, LP, WP Global, LLC, Warburg Pincus Partners I, LP, Warburg Pincus GP LLC, Warburg Pincus (Cayman) XI, LP, Warburg Pincus XI-C, LLC, Warburg Pincus Partners II (Cayman), LP, Warburg Pincus (Bermuda) Private Equity GP Ltd., Warburg Pincus & Co., WP XI, LP, Bull Co-Invest, LP, Warburg Pincus Private XI, LP, Warburg Pincus Partners II, LP, Warburg Pincus Partners II Holdings, LP, Warburg Pincus Partners GP LLC, Warburg Pincus Partners II Holdings (Cayman), LP, WPP II Administrative (Cayman), LLC and their respective affiliates, members, officers, directors, partners, and limited partners.

j.The phrase “Settling Defendants” refers to Sotera Health LLC and Sterigenics U.S., LLC.

k.The phrase “Eligible Claimants” refers to the Plaintiffs and Clients with Unfiled Claims, as reflected on Appendices A and B, as supplemented to add any additional plaintiffs or retained clients.

l.The phrase “Covered Claims” refers to the following categories of claims:

i.All claims, past, present, and future, alleged or that could have been alleged for any injury, harm, or damages, and seeking any form of relief, including money damages, restitution, punitive or exemplary damages, injunctive relief, or any other form of relief, related to or arising from alleged use and/or emissions of ethylene oxide from Sterigenics US’s operations in or around Willowbrook, Illinois (“Willowbrook Claims”), including but not limited to all claims against Sterigenics US as successor to Sterigenics EO, Inc., IBA S&I, Inc., Griffith Micro Science, Inc., Micro-Biotrol, Inc., and Micro-Biotrol Company related to the operations of any of those companies in or around Willowbrook, Illinois; and

ii.All claims, past, present, and future, alleged or that could have been alleged in the Bachoe et al. v. Sotera Health Company, et al. action filed on November 1, 2022 in the Circuit Court of Cook County (Case No. 2022-L- 009825), the Bachoe et al. v. Sotera Health Company, et al. action now pending in the U.S. District Court for the Northern District of Illinois (Case No. 22-cv-06292), and any other actual or potential actions seeking to challenge any transfer of assets to or from Sterigenics U.S., LLC, Sotera Health LLC, or any other Released Parties to any other entity or person.

m.The phrase “Other Facility Claims” refers to claims by any individual or entity relating to any other facility (other than a facility in or around Willowbrook, Illinois) owned or operated by any Released Parties and for which Plaintiffs’ Counsel serves as counsel of record or referral counsel. A list of all Other Facility Claims will be provided to Settling Defendants as Appendix G by no later than January 27th, 2023. PEC represents and warrants that they are not currently pursuing any Other Facility Claims, regardless of whether they are counsel of record or referral counsel, other than those listed on Appendix G.

n.The phrase “Released Parties” refers to Sotera Health, Sterigenics US, Warburg Pincus, GTCR, and all their affiliates, predecessors, successors, direct or indirect parents, direct or indirect subsidiaries, assigns, as well as any current, former, direct or indirect partners, managers, members, shareholders, employees, directors, officers, management companies, incorporators, investors, landlords, tenants, suppliers, service providers, customers, consultants, attorneys, agents, declarants, affiants or other representatives, including without limitation [***]. Released Parties also refers to the Released Parties’ insurers, including without limitation Steadfast Insurance Company/Zurich Insurance Group and National Union/AIG.

o.The phrase “Good Faith Settlement” refers to a settlement per the terms of this Term Sheet that is approved by the Circuit Court of Cook, Illinois, County Law Division, as having been entered into in good faith, pursuant to 740 ILCS 100/2.

3.Establishment of Settlement Program

a.PEC represents and warrants that the lists of Plaintiffs and Clients with Unfiled Claims reflected in Appendices A and B is complete and accurate. PEC represents and warrants that there are 870 Eligible Claimants, as reflected on Appendices A and B. PEC further affirm that they have not been retained by any individuals with Covered Claims other than those identified in Appendices A, B, and C, and PEC are not aware of any other individuals who have filed or plan to file Covered Claims.

b.The Parties will cooperate in establishing a Settlement Program and associated documents that comply in all respects with applicable state Rules of Professional Responsibility regarding aggregate settlements including Illinois Rule of Professional Conduct 1.8(g).

c.By participating in the Settlement Program and obtaining a settlement allocation for Eligible Claimant client(s), a Non-PEC Firm agrees to:

i.the Settlement Program Procedures set forth in Paragraph 4 below, including the requirement to provide information regarding Opt-Outs and any client whose status is uncertain, as if the Non-PEC Firm was a PEC member;

ii.the Confidentiality terms described in Paragraph 10 below, including the agreement not to identify Settling Defendants or Released Parties by name in any marketing communications, including websites, as if the Non-PEC Firm was a PEC member; and

iii.other conditions mutually agreed-upon by the Settling Defendants and PEC.

d.The Parties agree to cooperate in seeking a Court Order that facilitates the administration of the Settlement Program and the Settling Defendants’ evaluation of Opt-Outs, including by requiring Non-PEC Firms to comply with Settlement Program Procedures as a condition of participating in the Settlement Program.

e.The associated documents to be prepared by the Parties will include a release of Covered Claims (“Release”) for execution by individual Eligible Claimants who choose to accept their settlement allocation. Eligible Claimants who accept their settlement allocation and execute the Release will be “Settling Claimants”.

f.In the Release, Settling Claimants shall agree to release and covenant not to sue the Released Parties for all Covered Claims and any claims that are or could have been brought against any Released Parties relating to the Covered Claims or based on the conduct alleged in the litigation relating to any Covered Claims.

i.The Settling Claimants shall further expressly acknowledge and agree to release any rights they may have regarding claims relating to or arising from any Covered Claims that the Settling Claimant does not know or suspect to exist in his or her favor at the time of executing the Release and that, if known by him or her, would have materially affected his or her settlement with the Released Parties. The Settling Claimants expressly and knowingly waive any statutory or judicial provisions, rulings, or mandates to the contrary.

ii.Settling Claimants further agree to release all claims, past, present, and future, alleged or that could have been alleged against insurers who have any of the Released Parties as a Named Insured, including but not limited to Steadfast Insurance Company/Zurich Insurance Group and National Union/AIG, relating to or arising from any Covered Claims. For avoidance of doubt, Released Parties maintain, and do not release, any claims they may have against their insurers.

g.The Release will further require that, if any Settling Claimant settles with any third party against whom claims are not released through this settlement (collectively, “Non-Settling Third Parties”), the Settling Claimant will obtain a release from the Non-Settling Third Party for Released Parties for any claim for indemnity, contribution, or similar theory. If any Settling Claimant obtains a judgment against any Non-Settling Third Party, such Settling Claimant will not execute on any portion of that judgment that the Non-Settling Third Party successfully seeks from Released Parties via a claim for indemnity or contribution or similar claim. Settling Claimants agree to indemnify Released Parties for any claims for indemnity or contribution brought by any Non-Settling Third Parties against Released Parties arising from or relating to Settled Claims.

h.The Settlement Agreement will contain provisions that require all Plaintiffs’ Counsel, subject to the exercise of their independent professional judgment, to recommend participating in the settlement to each of his/her clients.

4.Settlement Program Procedures

a.The Settlement Program shall include a Claims Administrator who will serve in a capacity as determined by the PEC, to include evaluating appropriate documentation and applying a claim valuation formula or matrix to determine each Eligible Claimant’s settlement allocation amount. The Settlement Program shall also include an Administrator of the Qualified Settlement Fund (“QSF”) who will be responsible for distributing the settlement funds to be paid to each Settling Claimant. The QSF Administrator and the Claims Administrator may be the same person.

b.The Claims Administrator and QSF Administrator will be selected by the PEC.

c.Each Eligible Claimant will receive notice of their individual settlement allocation amount along with the other disclosures, including any required by Illinois Rule of Professional Conduct 1.8(g). Within 30 days of receiving all required disclosures along with their individual settlement allocation amount as determined by the Claims Administrator, each Eligible Claimant who chooses to accept their settlement allocation and become a Settling Plaintiff must execute the agreed upon Release (“Opt In Deadline”).

i.PEC can request a 30-day extension of the Opt In Deadline, which will not be unreasonably denied.

d.No later than three (3) days after the Opt In Deadline, PEC will confer with the Claims Administrator to prepare a written list of: (a) Settling Claimants; (b) those Eligible Claimants who have indicated that they have declined to accept their settlement allocation or the terms of the Release (“Opt-Out”); and (c) those Eligible Claimants whose status is unclear (for example, because the relevant Plaintiffs’ Counsel can no longer locate the Claimant or because the Claimant has ceased communicating with the relevant Plaintiffs’ Counsel). The written list shall be provided to the Settling Defendants no later than five (5) days after the Opt In Deadline.

e.The Claims Administrator will retain all executed Releases for the Settling Claimants until it is determined whether the Settling Defendants will be proceeding with the settlement or exercising its option to walk away from and void the settlement due to insufficient participation by the Eligible Claimants. The Claims Administrator must receive an executed Release from the Settling Claimant before any Settlement Funds may be paid to that Settling Claimant.

f.For each Opt-Out, Plaintiffs’ Counsel will complete a Plaintiff Fact Sheet (attached as Appendix E to this Term Sheet) and, to the extent applicable, the Mental Health Addendum (attached as Appendix F to this Term Sheet) and provide it to Settling Defendants within 15 days of the Opt In Deadline.

g.For each Eligible Claimant whose status is unclear as described in Paragraph 4(d) above, Plaintiffs’ Counsel will complete a Plaintiff Fact Sheet and, to the extent applicable, the Mental Health Addendum, to the best of their ability based on information in their possession and provide it to Settling Defendants within 15 days of the Opt In Deadline.

5.Participation.

a.Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement unless 99% of Eligible Claimants represented by the PEC opt into the settlement.

b.Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement unless 95% of the Claimants represented by Non- PEC Firms opt into the settlement.

c.If any Opt-Out fits into one or more of the following categories, then Settling Defendants will have the absolute option to walk away from and void the settlement:

i.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than two miles from the Willowbrook facility (as the crow flies) and a cancer injury;

ii.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than three miles from the Willowbrook facility (as the crow flies) and a breast cancer or hematopoietic cancer injury;

iii.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than two miles from the Willowbrook facility (as the crow flies) and more than one miscarriage;

iv.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than two miles from the Willowbrook facility (as the crow flies) and any injury to reproductive health besides miscarriage (including, but not limited to, infertility, stillbirth, premature birth, or birth defect);

v.Any Eligible Claimant alleging ethylene oxide exposure between 1984 and 1989 at any location (e.g., residences, workplaces, schools, etc.) closer than three miles from the Willowbrook facility (as the crow flies);

vi.Any Eligible Claimant alleging ethylene oxide exposure for 5 years or more at any location (e.g., residences, workplaces, schools, etc.) closer than three miles from the Willowbrook facility (as the crow flies); or

vii.Any Eligible Claimant alleging ethylene oxide exposure for 10 years or more at any location (e.g., residences, workplaces, schools, etc.) closer than four miles from the Willowbrook facility (as the crow flies).

d.After receiving the information described in Paragraph 4(d)-(g) above, Settling Defendants will have 15 days to evaluate the information provided (“Settling Defendants’ Review Period”) and, if applicable, to exercise its walk-away rights described in subsections (a)-(c) above, or elect to proceed with the settlement and waive the requirements of subsections (a)-(c) above. At the expiration of the Settling Defendants’ Review Period, Settling Defendants will notify the PEC and Claims Administrator of their decision whether to proceed with the settlement, if applicable. In the event the participation criteria have been met or, if applicable, Settling Defendants elect to proceed with the settlement (“Settling Defendants’ Decision to Proceed”), the settlement will be binding on all Settling Claimants who accepted their settlement allocation and submitted a Release.

e.Plaintiffs’ Counsel represent and warrant that there are 870 Eligible Claimants, as reflected on Appendices A and B. Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement if it is determined based on the claim formulation or matrix that 40 or more Eligible Claimants do not have valid claims or are otherwise deemed not entitled to any recovery.

f.In addition to the walk-away rights described above in sections 5(a)-(e), Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement if, before the final funding date for the QSF (as defined below), they learn of more than 5 other Willowbrook claims by Plaintiffs’ Counsel, not listed in Appendix A or B, against any of the Released Parties relating to any Covered Claim(s).

g.Any disagreement or dispute between the parties involving the participation level or percentage participation of claimants described in this Paragraph will be resolved by the parties submitting any such disagreement or dispute to Miles Ruthberg, whose resolution of the dispute will be final.

6.Funding Amount and Procedure.

a.The amount of settlement funds for the Settlement Program will be $285.5 million (“Settlement Funds”).

b.The Parties will establish an escrow account (“Escrow Account”). Settling Defendants will select the institution (“Escrow Agent”) to hold the Escrow Account with PEC’s consent, which will not be unreasonably withheld. The Parties will cooperate to prepare an escrow agreement with instructions to the Escrow Agent consistent with the obligations set forth in this Term Sheet.

c.The Parties will also establish an interest-bearing qualified settlement fund (“QSF”). PEC will select the financial institution to hold the qualified settlement fund with Settling Defendants’ consent, which will not be unreasonably withheld. The QSF shall be treated as being at all times a “qualified settlement fund” for US federal income tax purposes, and the Parties shall act accordingly.

d.Sterigenics U.S., LLC is exclusively responsible for paying the Settlement Funds to the Escrow Account.

e.Sotera Health Company agrees to be guarantor of Sterigenics U.S., LLC’s obligation to pay the Settlement Funds to the Escrow Account until said funds are deposited into the Escrow Account.

f.Sterigenics U.S., LLC will deposit the Settlement Funds in the Escrow Account or transmit the Settlement Funds to the designated Escrow Agent to be deposited into the Escrow Account by or on May 1, 2023, subject to the conditions set forth below in subsection (h).

g.Subject to the conditions set forth in subsection (h), the Escrow Agent will release the Settlement Funds from the Escrow Account to the QSF within 30 days of the final order on appeal affirming the GFSD (as defined below). If there is no appeal of the Court’s GFSD, the Escrow Agent will release the Settlement Funds to the QSF within 7 days of the expiration of the deadline to file an appeal from the Court’s GFSD, subject to the conditions set forth in subsection (h).

h.In the event of the failure of any of the conditions set forth below, the duties set forth in subsections (f) and (g) will be deferred until the conditions have been satisfied:

i.the continued operation of a stay on the actions set forth in Paragraph 8 below;

ii.the absence of any viable lawsuit challenging this Term Sheet or the Settlement Agreement; or

iii.compliance by PEC and Plaintiffs’ Counsel with all material duties and obligations set forth in this Term Sheet, the Settlement Agreement, and otherwise in connection with settlement.

i.In the event the Settling Defendants exercise their walk-away rights under this Term Sheet, or this Term Sheet otherwise becomes void, the duties set forth in subsections (f) and (g) are likewise void. In the event Sterigenics U.S., LLC has already deposited the Settlement Funds into the Escrow Account, those funds will be promptly returned by the Escrow Agent to Sterigenics U.S., LLC.

j.Any disagreement or dispute between the parties involving the conditions or obligations of the Parties described in this Paragraph will be resolved by the Parties submitting any such disagreement or dispute to Miles Ruthberg, whose resolution of the dispute will be final.

k.Fees incurred in connection with the administration of the Settlement Program, including fees of the Claims Administrator and any fees or costs associated with establishing and/or maintaining the QSF, are to be paid by Settling Claimants and/or Plaintiffs’ Counsel from the QSF, consistent with applicable state Rules of Professional Conduct.

l.Settling Defendants and their counsel have played no role in, will play no role in, and will neither take nor bear any responsibility for the allocation of Settlement Funds among the settling plaintiffs or the allocation of settlement funds between settling plaintiffs and Plaintiffs’ Counsel.

m.Sotera Health Company’s agreement to serve as guarantor of Sterigenics U.S., LLC’s obligation to pay the Settlement Funds to the Escrow Account does not constitute an admission of liability or responsibility as a parent company for the actions of Sterigenics U.S., LLC or any other subsidiary with respect to any of the Covered Claims.

7.Good Faith Settlement Determination and Funding

a.Upon satisfaction of the participation criteria set forth in Paragraphs 5(a)-(f), or the Settling Defendants elect to proceed with the settlement notwithstanding any walkaway rights triggered under Paragraphs 5(a)-(f), the parties will promptly file a motion for good-faith settlement determination (“GFSD”) pursuant to 740 ILCS 100/2,including an Ill. S. Ct. R. 304(a) finding.

b.The Parties will use best efforts to obtain a GFSD.

c.If a court does not enter a GFSD, or if the GFSD is overturned on appeal, the parties will return to mediation and use best efforts to resolve any issues.

8.Stay.

a.On January 9, 2023, the Parties will jointly seek a stay of (a) all pending cases related to the Covered Claims of Eligible Claimants listed on Appendices A and B for the purpose of finalizing the Settlement Agreement; and (b) the Bachoe et al. v. Sotera Health Company, et al. action now pending in the U.S. District Court for the Northern District of Illinois (Case No. 22-cv-06292).

b.The Parties will request the stays remain in place until the parties dismiss all pending Eligible Claims pursuant to Paragraph 9 below, or Settling Defendants walk away from the settlement pursuant to Paragraph 5(a)-(f).

c.The Parties’ agreement to the terms reflected in this Term Sheet is contingent on the grant of a stay as described in subsections (a)-(b) above.

d.In the event the Settling Defendants exercise their walk-away rights under this Term Sheet, or this Term Sheet otherwise becomes void, Plaintiffs may seek an immediate lifting of the stay set forth in 8(a).

9.Dismissal.

a.Settling Claimants who submitted a Release will dismiss with prejudice all their pending lawsuits and appeals within 10 days of the date the Escrow Agent releases the Settlement Funds for the Willowbrook Group QSF in Paragraph 6(g).

10.Confidentiality.

a.The Parties agree to maintain confidentiality of the fact of this Term Sheet, any Settlement Agreement, and the terms of such Term Sheet and Settlement Agreement, until the filing of a motion to obtain a stay of litigation. PEC also can discuss the fact, but not amount, of the settlement with Griffith Foods.

b.Eligible Claimants and PEC will not issue any press releases, press briefings, tweets, Instagram posts, or any other social media posts relating to the Term Sheet, any Settlement Agreement, or the terms of the Term Sheet and Settlement Agreement. PEC will not identify Settling Defendants or Released Parties by name in any marketing communications, including websites, but may otherwise discuss information in the public domain.

c.PEC acknowledge that Settling Defendants will be disclosing the principal terms of the overall settlement (including the total amount to be paid by the Settling Defendants) and may also disclose this Term Sheet and the Willowbrook Trial

Plaintiffs’ Term Sheet if the Settling Defendants determine that such disclosure is required by federal securities laws and regulations.

d.The Parties agree that while nothing in this Term Sheet is or will be intended to operate as a restriction on the right of PEC to practice law within the meaning of the relevant states’ equivalent to Rule 5.6(b) of the ABA Model Rules of Professional Conduct in any jurisdiction in which the firm may practice or whose Rules may otherwise apply, PEC represents that they and their respective law firm have no present intention to solicit, accept, or represent new clients for the purpose of bringing any Covered Claim against any Released Party.

e.The Parties agree that while nothing in this Term Sheet is or will be intended to operate as a restriction on the right of PEC to practice law within the meaning of the relevant states’ equivalent to Rule 5.6(b) of the ABA Model Rules of Professional Conduct in any jurisdiction in which the firm may practice or whose Rules may otherwise apply, PEC affirm that, to the best of their knowledge, they have ceased all firm-directed and direct advertising for Covered Claims and have no present intention to resume such advertising. This includes purchases of Google ad words, emails or other communications with client databases regarding Covered Claims and any other solicitation originating from any PEC in any medium, including television, billboards, websites, blogs, internet ads or pop-ups, newspapers, magazines, Facebook, Twitter, Instagram, or other social media outlets.

11.Attorneys’ Fees, Taxes, Liens and Rights of Subrogation.

a.Released Parties have no responsibility whatsoever for the payment of Settling Claimants’ attorneys’ fees or costs, or for the payment of any taxes owed by Settling Claimants, or for satisfaction of liens associated with allocations of funds.

b.Settling Claimants are solely responsible for their respective liens and will indemnify and hold harmless Settling Defendants and all Released Parties from claims by lienholders, actual or asserted.

c.The Parties will establish a process for identifying and resolving liens or subrogation or subrogated claims prior to the funding of the QSF.

d.Settling Claimants agree that any interest in, lien on, or right of subrogation in their Covered Claim by or belonging to any and all entities and individuals, including without limitation any governmental agencies or authorities, attorneys, litigation funders, healthcare providers, and/or insurers, will be satisfied by the Settling Claimant’s allocated payment.

e.Each PEC indemnifies and agrees to hold harmless each Settling Defendant and all Released Parties from any claim of any holder of a lien on PEC, to the extent such lien is applicable exclusively to Plaintiffs’ Counsel and not to any Settling Claimant.

f.Released Parties are not responsible for liens or subrogation claims against settlement payments or the costs and expenses incurred in resolving any such liens or subrogation claims against settlement payments.

12.Heirs.

a.For any wrongful death case, the Settling Claimant shall represent and warrant in their Release that they (a) are authorized to resolve the claim of the deceased Eligible Claimant on behalf of the heirs and estate of the deceased Eligible Claimant, (b) that they will ensure that the further allocation of the settlement funds related to the deceased Eligible Claimant’s claim is handled pursuant to applicable law, and (c) that they will indemnify the Released Parties against any claims related to the allocation of the settlement funds among the heirs and estate. The parties agree that Released Parties are entitled to rely on these representations.

13.The dates for commencing or completing of certain actions with this agreement are goals, and not necessarily deadlines. If a goal date or dates are not met on the precise date as set forth herein, the Parties will work together to adjust the timeline goals in order for the Parties to accomplish their agreed upon desire to complete this settlement.

14.With the exception of the Settling Defendants, and notwithstanding any other provision herein, none of the Released Parties has any obligation to the Settling Claimants, financial or otherwise, under this Term Sheet or otherwise as a result of or in consideration for the Settling Claimants opting into the settlement or for releasing and covenanting not to sue the Released Parties.

15.The Parties shall cooperate with respect to compliance with any required tax reporting, including by using reasonable efforts to provide (or to cause Plaintiffs’ Counsel, Plaintiffs, and Clients to provide) any information or tax forms reasonably requested by the Settling Defendants or the Claims Administrator. No amount of taxes shall be withheld by any person making a payment pursuant to the settlement in accordance with this Term Sheet except to the extent required by applicable law.

16.Governing Law. This Term Sheet shall be governed by and construed in accordance with the law of the State of Illinois without regard to any choice-of-law rules that would require the application of the law of another jurisdiction. Any such proceedings relating to this Term Sheet shall be filed in the Circuit Court of Cook County, Illinois.

17.Electronic Signatures. This Term Sheet and any amendments thereto, to the extent signed and delivered by means of a facsimile machine or electronic scan (including in the form of an Adobe Acrobat PDF file format), shall be treated in all manner and respects as an original agreement and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

18.Counterparts. This Term Sheet may be executed in any number of counterparts, each of which shall be an original and all of which shall together constitute one and the same instrument. It shall not be necessary for any counterpart to bear the signature of all Parties. Counsel for any Party shall be authorized to assemble a composite counterpart which shall consist of one copy of each page, except the signature pages, together with multiple counterpart signature pages executed on behalf of every party to this Term Sheet. The composite counterpart may then be used by any Party for all purposes as the complete signed and executed Term Sheet.

[Continued on subsequent page]

Plaintiffs' Executive Committee, on Behalf of

Plaintiffs' Counsel


/s/ Antonio Romanucci
Antonio Romanucci
Romanucci & Blandin, LLC


/s/ Todd A. Smith
Todd A. Smith
Smith LaCien, LLP


/s/ Daniel M. Kotin
Daniel M. Kotin
Tomasik Kotin Kasserman, LLC


/s/ Shawn M. Collins
Shawn M. Collins
The Collins Law Firm, P.C.


/s/ Steven A. Hart
Steven A. Hart
Hart McLaughlin & Eldridge, LLC


/s/ Scott A. Entin
Scott Entin
Miner, Barnhill & Galland, P.C.


/s/ Patrick A. Salvi, II
Patrick A. Salvi, II
Salvi, Schostok & Pritchard P.C.

Settling Defendants


/s/ Matthew J. Klaben
Matthew J. Klaben
Sotera Health LLC
January 9, 2023


/s/ Matthew J. Klaben
Matthew J. Klaben
Sterigenics U.S., LLC
January 9, 2023

As Guarantor


/s/ Alexander Dimitrief
Alexander Dimitrief
Sotera Health Company
January 9, 2023

Willowbrook: Group Settlement Term Sheet Appendix A

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

[***]

18‐L‐011004

Smith Lacien

Breast Cancer

[***]

18‐L‐011252

RB/HME

Breast Cancer

[***]

19‐L‐009163

CLF/MBG

Multiple Myeloma

[***]

19‐L‐009167

Smith Lacien

NHL & Breast

[***]

19‐L‐009167

Smith Lacien

Schwanoma

[***]

19‐L‐009169

Smith Lacien

Breast Cancer

[***]

19‐L‐009170

Salvi, Schostok & Pritchard

Hodgkin's Lymphoma | Hashimotos |
Fertility Issues

[***]

19‐L‐009173

Salvi, Schostok & Pritchard

Non‐Hodgkins Lymphoma

[***]

19‐L‐009176

Tomasik Kotin Kasserman

Non‐Hodgkin's Lymphoma

[***]

19‐L‐009177

Tomasik Kotin Kasserman

Acute Myeloid Leukemia

[***]

19‐L‐009178

Tomasik Kotin Kasserman

Breast Cancer

[***]

19‐L‐009179

Tomasik Kotin Kasserman

Breast Cancer

[***]

19‐L‐009181

RB/HME

Breast Cancer

[***]

19‐L‐009182

RB/HME

ALL

[***]

19‐L‐009189

Smith Lacien

Breast cancer

[***]

19‐L‐009190

CLF/MBG

Mulitple Myeloma

[***]

19‐L‐009196

RB/HME

AML

[***]

19‐L‐009197

Wise Morrissey

Pancreatic Cancer

[***]

19‐L‐009198

RB/HME

Breast Cancer

[***]

19‐L‐009200

CLF/MBG

Breast Cancer

[***]

19‐L‐009202

CLF/MBG

Mantle Cell Lymphoma (NHL)

[***]

19‐L‐009205

CLF/MBG

Miscarriages

[***]

19‐L‐009205

CLF/MBG

NHL

[***]

19‐L‐009206

CLF/MBG

Breast Cancer

[***]

19‐L‐009207

CLF/MBG

Breast Cancer; Miscarriage

[***]

19‐L‐009213

CLF/MBG

ALL

[***]

19‐L‐009214

CLF/MBG

Breast Cancer; Miscarriages

[***]

19‐L‐009215

CLF/MBG

Sezary Syndrome (NHL)

[***]

19‐L‐009216

CLF/MBG

Breast Cancer

[***]

19‐L‐009362

Motherway & Napleton

Amyloidosis

[***]

19‐L‐009454

Motherway & Napleton

Breast Cancer

[***]

19‐L‐009508

CLF/MBG

ALL

[***]

19‐L‐009528

Nolan Law

Duodenal Adenocarcinoma

[***]

19‐L‐009732

Cavanagh Law Group

Follicular lymphoma/AML

[***]

19‐L‐011510

Motherway & Napleton

Breast Cancer

[***]

19‐L‐011682

CLO

Breast Cancer

[***]

19‐L‐013486

Tomasik Kotin Kasserman

Breast Cancer

[***]

19‐L‐013488

Tomasik Kotin Kasserman

Breast Cancer

[***]

19‐L‐013493

Tomasik Kotin Kasserman

Breast Cancer

[***]

19‐L‐013517

CLF/MBG

Breast Cancer/CLL

[***]

19‐L‐013518

CLF/MBG

Breast Cancer

[***]

19‐L‐013522

CLF/MBG

Breast Cancer

[***]

19‐L‐013537

RB/HME

NHL

[***]

19‐L‐013538

RB/HME

NHL

[***]

19‐L‐013539

RB/HME

NHL

[***]

19‐L‐013540

WSOR

ALL

[***]

19‐L‐013541

RB/HME

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

[***]

19‐L‐013544

RB/HME

[***]

19‐L‐013545

RB/HME

CLL

[***]

19‐L‐013545

RB/HME

NHL

[***]

19‐L‐013546

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma ‐ Diffuse
Large B‐Cell

[***]

19‐L‐013550

Salvi, Schostok & Pritchard

Breast Cancer ‐ Bilateral

[***]

19‐L‐013551

Salvi, Schostok & Pritchard

Lymphoma, Follicular & Large B‐Cell
Lymphoma

[***]

19‐L‐013552

Salvi, Schostok & Pritchard

Breast Cancer

[***]

19‐L‐013554

WSOR

Breast Cancer

[***]

19‐L‐013562

RB/HME

ALL

[***]

19‐L‐013568

WSOR

Large B Cell Lymphoma

[***]

19‐L‐013575

CLF/MBG

Breast Cancer

[***]

19‐L‐013576

CLF/MBG

NHL

[***]

19‐L‐013857

CLF/MBG

NHL

[***]

19‐L‐013860

CLF/MBG

Breast Cancer

[***]

19‐L‐014265

CLF/MBG

Waldenstrom’s Macroglobulinemia

[***]

20‐L‐005064

TPMB

breast cancer

[***]

20‐L‐006260

KJS

Chronic Myelogenous Leukemia

[***]

20‐L‐007672

CLO

None ;Breast Cancer; histiocytosis

[***]

20‐L‐007672

CLO

Histiocytosis

[***]

20‐L‐008669

RB/HME

[***]

20‐L‐008671

RB/HME

ALL

[***]

20‐L‐008673

RB/HME

Breast/Lymphome

[***]

20‐L‐008675

RB/HME

Breast Cancer

[***]

20‐L‐008676

RB/HME

Breast Cancer

[***]

20‐L‐008677

RB/HME

NHL

[***]

20‐L‐008678

RB/HME

Pancreatic Cancer

[***]

20‐L‐008682

RB/HME

Miscarriages

[***]

20‐L‐008686

Tomasik Kotin Kasserman

Breast Cancer and Infertility

[***]

20‐L‐008688

Tomasik Kotin Kasserman

Breast Cancer and Infertility

[***]

20‐L‐008691

Tomasik Kotin Kasserman

Breast Cancer

[***]

20‐L‐008692

Tomasik Kotin Kasserman

Stomach Cancer

[***]

20‐L‐008695

RB/HME

NHL (Burkett's)

[***]

20‐L‐008699

RB/HME

Breast cancer; 2 miscarriages;
infertility

[***]

20‐L‐008701

RB/HME

Breast Cancer

[***]

20‐L‐008702

RB/HME

Testicular Cancer

[***]

20‐L‐008704

RB/HME

Follicular Lymphoma

[***]

20‐L‐008705

RB/HME

Breast Cancer

[***]

20‐L‐008706

RB/HME

Stomach Cancer

[***]

20‐L‐008708

RB/HME

Miscarriages

[***]

20‐L‐008709

RB/HME

Miscarriages

[***]

20‐L‐008715

RB/HME

Breast Cancer

[***]

20‐L‐008716

Motherway & Napleton

Breast Cancer

[***]

20‐L‐008718

Motherway & Napleton

Idiopathic Pulmonary Fibrosis

[***]

20‐L‐008719

KJS

Breast Cancer

[***]

20‐L‐008720

RB/HME

Miscarriages

[***]

20‐L‐008721

KJS

NHL

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

[***]

20‐L‐008722

RB/HME

Miscarriages

[***]

20‐L‐008724

CLF/MBG

Breast Cancer

[***]

20‐L‐008737

TPMB

pituitary adenoma

[***]

20‐L‐008740

RB/HME

Breast Cancer

[***]

20‐L‐008741

RB/HME

Bladder Cancer; Prostate Cancer

[***]

20‐L‐008741

RB/HME

Miscarriages

100

[***]

20‐L‐008742

RB/HME

Breast Cancer

101

[***]

20‐L‐008743

RB/HME

NHL

102

[***]

20‐L‐008745

RB/HME

ALL

103

[***]

20‐L‐008746

RB/HME

Breast Cancer

104

[***]

20‐L‐008748

RB/HME

Breast Cancer

105

[***]

20‐L‐008749

RB/HME

Breast Cancer

106

[***]

20‐L‐008750

RB/HME

Breast Cancer

107

[***]

20‐L‐008752

RB/HME

Breast Cancer

108

[***]

20‐L‐008753

RB/HME

NHL

109

[***]

20‐L‐008755

RB/HME

Breast Cancer

110

[***]

20‐L‐008756

RB/HME

Kidney Cancer

111

[***]

20‐L‐008757

RB/HME

Breast Cancer

112

[***]

20‐L‐008758

RB/HME

Breast Cancer

113

[***]

20‐L‐008759

RB/HME

Breast Cancer

114

[***]

20‐L‐008762

RB/HME

Breast Cancer

115

[***]

20‐L‐008764

RB/HME

116

[***]

20‐L‐008765

RB/HME

117

[***]

20‐L‐008766

Power Rogers

Breast Cancer

118

[***]

20‐L‐008766

Power Rogers

Leukemia

119

[***]

20‐L‐008769

RB/HME

Breast Cancer

120

[***]

20‐L‐008771

RB/HME

AML/Fertility

121

[***]

20‐L‐008774

Corboy & Demetrio

Breast Cancer

122

[***]

20‐L‐008776

Salvi, Schostok & Pritchard

Hodgkin's Lymphoma

123

[***]

20‐L‐008779

RB/HME

Breast Cancer

124

[***]

20‐L‐008787

Power Rogers

NHL

125

[***]

20‐L‐008791

Wise Morrissey

Brain Cancer

126

[***]

20‐L‐008792

Wise Morrissey

Breast Cancer

127

[***]

20‐L‐008794

RB/HME

NHL

128

[***]

20‐L‐008795

RB/HME

Kidney Cancer

129

[***]

20‐L‐008797

RB/HME

Breast Cancer

130

[***]

20‐L‐008797

RB/HME

Lymphoma

131

[***]

20‐L‐008799

RB/HME

Lymphoma

132

[***]

20‐L‐008800

RB/HME

Breast Cancer

133

[***]

20‐L‐008803

RB/HME

Kidney Cancer

134

[***]

20‐L‐008806

RB/HME

Breast Cancer

135

[***]

20‐L‐008809

RB/HME

Breast Cancer

136

[***]

20‐L‐008810

RB/HME

Miscarriages

137

[***]

20‐L‐008812

RB/HME

Leukemia

138

[***]

20‐L‐008816

Power Rogers

Multiple Myeloma

139

[***]

20‐L‐008825

Power Rogers

Breast Cancer

140

[***]

20‐L‐008826

Power Rogers

Non Hodgkin's Lymphoma

141

[***]

20‐L‐008828

Power Rogers

Non Hodgkin's Lymphoma

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

142

[***]

20‐L‐008829

Power Rogers

Breast Cancer

143

[***]

20‐L‐008830

Power Rogers

Leukemia

144

[***]

20‐L‐008831

Corboy & Demetrio

Acute Lymphoblastic Leukemia

145

[***]

20‐L‐008833

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma

146

[***]

20‐L‐008834

Power Rogers

Breast Cancer

147

[***]

20‐L‐008835

Power Rogers

Breast Cancer

148

[***]

20‐L‐008838

Power Rogers

Breast Cancer

149

[***]

20‐L‐008840

Power Rogers

Breast Cancer

150

[***]

20‐L‐008841

Cavanagh Law Group

Brain tumor/death

151

[***]

20‐L‐008842

Power Rogers

Breast Cancer

152

[***]

20‐L‐008845

CLF/MBG

Breast Cancer

153

[***]

20‐L‐008845

CLF/MBG

Miscrriage

154

[***]

20‐L‐008847

Power Rogers

Breast Cancer

155

[***]

20‐L‐008850

Power Rogers

Breast Cancer

156

[***]

20‐L‐008851

Cavanagh Law Group

Osteosarcoma/death

157

[***]

20‐L‐008853

Power Rogers

Multiple Myeloma

158

[***]

20‐L‐008860

Power Rogers

Breast Cancer

159

[***]

20‐L‐008862

Corboy & Demetrio

Bladder Cancer

160

[***]

20‐L‐008868

Smith Lacien

B‐cell Chronic Lymphocytic Leukemia

161

[***]

20‐L‐008869

Smith Lacien

Non‐Hodgkin's Lymphoma

162

[***]

20-L-008870

Smith Lacien

Hodgkin's Lymphoma Stage 2b

163

[***]

20‐L‐008871

Smith Lacien

Follicular Lymphoma; Tonsil Carcinoma

164

[***]

20‐L‐008872

Smith Lacien

Blood Cancer; Uterine Cancer;
Myeloproliferative Neoplasim

165

[***]

20‐L‐008875

Salvi, Schostok & Pritchard

Breast Cancer

166

[***]

20‐L‐008876

Salvi, Schostok & Pritchard

Leukemia Lymphocytic, Chronic

167

[***]

20‐L‐008879

Salvi, Schostok & Pritchard

Miscarriages (4)

168

[***]

20‐L‐008880

Salvi, Schostok & Pritchard

Breast Cancer

169

[***]

20‐L‐008881

Salvi, Schostok & Pritchard

Leukemia (MDS)

170

[***]

20‐L‐008882

Smith Lacien

Breast Cancer

171

[***]

20‐L‐008883

Salvi, Schostok & Pritchard

Breast Cancer

172

[***]

20‐L‐008884

RB/HME

Breast Cancer

173

[***]

20‐L‐008885

RB/HME

Miscarriages

174

[***]

20‐L‐008887

RB/HME

Myeloid Leukemia

175

[***]

20‐L‐008889

Salvi, Schostok & Pritchard

Lymphoma | Myelodysplastic
Syndromes

176

[***]

20‐L‐008891

Smith Lacien

Uterine Cancer; Breast Cancer

177

[***]

20‐L‐008903

Salvi, Schostok & Pritchard

Leukemia, Chronic Myeloid

178

[***]

20‐L‐008905

Salvi, Schostok & Pritchard

Breast Cancer

179

[***]

20‐L‐008909

Smith Lacien

Breast Cancer

180

[***]

20‐L‐008911

Salvi, Schostok & Pritchard

Breast Cancer ‐ Stage 3 triple negative

181

[***]

20‐L‐008914

Salvi, Schostok & Pritchard

Breast Cancer

182

[***]

20‐L‐008917

Salvi, Schostok & Pritchard

Breast Cancer, Stage III

183

[***]

20‐L‐008919

Power Rogers

Breast Cancer

184

[***]

20‐L‐008923

Smith Lacien

Breast Cancer

185

[***]

20‐L‐008925

CLO

Breast Cancer

186

[***]

20‐L‐008929

Salvi, Schostok & Pritchard

Lung cancer

187

[***]

20‐L‐008930

Salvi, Schostok & Pritchard

Breast cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

188

[***]

20‐L‐008932

CLO

Breast Cancer

189

[***]

20‐L‐008933

CLO

Stomach Adenocarcinoma

190

[***]

20‐L‐008934

Salvi, Schostok & Pritchard

Breast Cancer

191

[***]

20‐L‐008937

CLO

Thyroid Cancer

192

[***]

20‐L‐008943

WSOR

Breast Cancer

193

[***]

20‐L‐008945

Smith Lacien

Breast Cancer; Lung Cancer

194

[***]

20‐L‐008945

Smith Lacien

Non‐Hodgkins Lymphoma

195

[***]

20‐L‐008946

Salvi, Schostok & Pritchard

Breast Cancer

196

[***]

20‐L‐008948

WSOR

Breast & Uterine Cancer

197

[***]

20‐L‐008949

Salvi, Schostok & Pritchard

Brain & Lung Cancers

198

[***]

20‐L‐008950

Salvi, Schostok & Pritchard

Brain tumor

199

[***]

20‐L‐008951

Salvi, Schostok & Pritchard

Leukemia ‐ Acute Myeloid

200

[***]

20‐L‐008952

WSOR

Bladder Cancer

201

[***]

20‐L‐008953

Salvi, Schostok & Pritchard

Lung Cancer (non‐small cell
adenocarcinoma)

202

[***]

20‐L‐008957

WSOR

Fybromyoxoid Sarcoma

203

[***]

20‐L‐008958

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma

204

[***]

20‐L‐008959

WSOR

Pancreatic Cancer

205

[***]

20‐L‐008961

Salvi, Schostok & Pritchard

Gastrointestinal Cancer (stomach)

206

[***]

20‐L‐008962

Salvi, Schostok & Pritchard

Stomach cancer

207

[***]

20‐L‐008966

RB/HME

Colon Cancer

208

[***]

20‐L‐008971

RB/HME

Miscarriages

209

[***]

20‐L‐008989

WSOR

Prostate Cancer

210

[***]

20‐L‐009000

WSOR

Prostate Cancer

211

[***]

20‐L‐009006

Smith Lacien

Multiple Myeloma

212

[***]

20‐L‐009012

CLF/MBG

Multiple Myeloma

213

[***]

20‐L‐009018

CLF/MBG

Breast Cancer

214

[***]

20‐L‐009277

RB/HME

Cancer

215

[***]

20‐L‐009296

CLF/MBG

Breast Cancer

216

[***]

20‐L‐009380

CLF/MBG

Hodgkin's Lymphoma

217

[***]

20‐L‐012228

CLF/MBG

Breast cancer

218

[***]

20‐L‐012899

CLF/MBG

Breast Cancer, Miscarriage

219

[***]

21‐L_011277

Smith Lacien

Non‐Hodgkin's Lymphoma

220

[***]

21‐L‐001619

McNabola

Uterine/Endometrial

221

[***]

21‐L‐002646

Karamanis

Facial Adenoma?

222

[***]

21‐L‐006899

Salvi, Schostok & Pritchard

Breast Cancer

223

[***]

21‐L‐008020

RB/HME

Breast Cancer

224

[***]

21‐L‐008023

RB/HME

Breast Cancer

225

[***]

21‐L‐008035

RB/HME

Breast Cancer

226

[***]

21‐L‐008090

RB/HME

Multiple Myeloma

227

[***]

21‐L‐008685

Salvi, Schostok & Pritchard

Multiple Myeloma

228

[***]

21‐L‐008692

Salvi, Schostok & Pritchard

Mantle Cell Lymphoma (NHL)

229

[***]

21‐L‐008696

Salvi, Schostok & Pritchard

Breast Cancer

230

[***]

21‐L‐008698

Salvi, Schostok & Pritchard

Breast Cancer

231

[***]

21‐L‐009476

Salvi, Schostok & Pritchard

Breast Cancer

232

[***]

21‐L‐010808

Salvi, Schostok & Pritchard

Breast Cancer

233

[***]

21‐L‐011256

CLF/MBG

Breast Cancer

234

[***]

21‐L‐011260

CLF/MBG

Breast Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

235

[***]

21‐L‐011261

Smith Lacien

Breast Cancer

236

[***]

21‐L‐011263

CLF/MBG

Breast Cancer

237

[***]

21‐L‐011265

CLF/MBG

Breast Cancer

238

[***]

21‐L‐011266

Smith Lacien

Large Cell B Lymphoma

239

[***]

21‐L‐011268

Smith Lacien

T‐Cell Acute Lymphocytic Leukemia

240

[***]

21‐L‐011269

Smith Lacien

Non‐Hodgkin's Lymphoma

241

[***]

21‐L‐011270

Smith Lacien

Breast Cancer; Fertility Issues

242

[***]

21‐L‐011273

CLF/MBG

Breast Cancer

243

[***]

21‐L‐011274

Smith Lacien

Leukemia; Celiac Disease; Anemia

244

[***]

21‐L‐011276

CLF/MBG

Breast Cancer

245

[***]

21‐L‐011278

CLF/MBG

Breast Cancer

246

[***]

21‐L‐011279

Smith Lacien

Non‐Hodgkins Lymphoma

247

[***]

21‐L‐011280

Smith Lacien

Breast Cancer

248

[***]

21‐L‐011281

Smith Lacien

Non‐Hodgkin's Lymphoma; Breast
Cancer

249

[***]

21‐L‐011283

Smith Lacien

Mast Cell Leukemia, Advanced
Systemic Mastocytosis, Myelodysplastic Syndrome.

250

[***]

21‐L‐011284

Smith Lacien

Non‐Hodgkin's Lymphoma

251

[***]

21‐L‐011285

Smith Lacien

Breast Cancer

252

[***]

21‐L‐011286

Smith Lacien

Prostate Cancer; Non‐Hodgkins
Lymphoma

253

[***]

21‐L‐011288

Smith Lacien

Large Cell B Type Non‐Hodgkin's
Lymphoma

254

[***]

21‐L‐011290

Smith Lacien

Breast Cancer

255

[***]

21‐L‐011292

Smith Lacien

Breast Cancer

256

[***]

21‐L‐011293

CLF/MBG

Hogkin's Lymphoma

257

[***]

21‐L‐011293

CLF/MBG

Hogkin's Lymphoma

258

[***]

21‐L‐011294

Smith Lacien

Breast Cancer

259

[***]

21‐L‐011295

Smith Lacien

Intertility; Breast Cancer

260

[***]

21‐L‐011298

Smith Lacien

Breast Cancer

261

[***]

21‐L‐011299

Smith Lacien

Breast Cancer

262

[***]

21‐L‐011300

CLF/MBG

Breast Cancer

263

[***]

21‐L‐011301

Smith Lacien

Larynx Cancer; Lymphoma

264

[***]

21‐L‐011302

Smith Lacien

Breast Cancer; Paillary Thyroid
Carcinoma; Basal Cell Carcinoma

265

[***]

21‐L‐011303

CLF/MBG

NHL

266

[***]

21‐L‐011304

CLF/MBG

Breast Cancer

267

[***]

21‐L‐011305

Smith Lacien

Breast Cancer

268

[***]

21‐L‐011305

Smith Lacien

Chronic Myelogenous Leukemia

269

[***]

21‐L‐011306

CLF/MBG

Breast Cancer

270

[***]

21‐L‐011306

CLF/MBG

Breast Cancer

271

[***]

21‐L‐011308

CLF/MBG

Stomach Cancer

272

[***]

21‐L‐011309

CLF/MBG

Miscarriages

273

[***]

21‐L‐011313

CLF/MBG

Carcinoid Tumor

274

[***]

21‐L‐011313

CLF/MBG

Myelodysplastic Syndrome

275

[***]

21‐L‐011317

CLF/MBG

Breast Cancer

276

[***]

21‐L‐011318

Tomasik Kotin Kasserman

Infertility

277

[***]

21‐L‐011319

CLF/MBG

Breast Cancer

278

[***]

21‐L‐011319

CLF/MBG

Breast Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

279

[***]

21‐L‐011319

CLF/MBG

Smouldering Myeloma

280

[***]

21‐L‐011320

Tomasik Kotin Kasserman

Breast Cancer

281

[***]

21‐L‐011322

CLF/MBG

Breast Cancer

282

[***]

21‐L‐011323

Tomasik Kotin Kasserman

Multiple Myelomia

283

[***]

21‐L‐011324

Tomasik Kotin Kasserman

Breast Cancer

284

[***]

21‐L‐011326

Tomasik Kotin Kasserman

Infertility

285

[***]

21‐L‐011327

Tomasik Kotin Kasserman

Leukemia

286

[***]

21‐L‐011329

Tomasik Kotin Kasserman

Stomach Cancer

287

[***]

21‐L‐011330

RB/HME

Breast Cancer

288

[***]

21‐L‐011331

Tomasik Kotin Kasserman

Breast Cancer

289

[***]

21‐L‐011332

Tomasik Kotin Kasserman

Breast Cancer

290

[***]

21‐L‐011333

Tomasik Kotin Kasserman

Birth Defects

291

[***]

21‐L‐011333

Tomasik Kotin Kasserman

Birth Defects

292

[***]

21‐L‐011333

Tomasik Kotin Kasserman

Birth Defects

293

[***]

21‐L‐011333

Tomasik Kotin Kasserman

Fertility Issues

294

[***]

21‐L‐011334

CLF/MBG

Breast Cancer

295

[***]

21‐L‐011335

RB/HME

NHL

296

[***]

21‐L‐011336

RB/HME

NHL

297

[***]

21‐L‐011337

RB/HME

ALL

298

[***]

21‐L‐011338

Salvi, Schostok & Pritchard

Neuroblastoma

299

[***]

21‐L‐011338

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma, Stage II

300

[***]

21‐L‐011343

Tomasik Kotin Kasserman

Breast Cancer

301

[***]

21‐L‐011347

Salvi, Schostok & Pritchard

Breast Cancer

302

[***]

21‐L‐011348

CLF/MBG

Breast Cancer

303

[***]

21‐L‐011349

Tomasik Kotin Kasserman

Infertility

304

[***]

21‐L‐011350

Tomasik Kotin Kasserman

Fertility Issues

305

[***]

21‐L‐011351

Tomasik Kotin Kasserman

Bladder Cancer

306

[***]

21‐L‐011352

CLF/MBG

Breast Cancer

307

[***]

21‐L‐011353

Salvi, Schostok & Pritchard

Breast Cancer X2

308

[***]

21‐L‐011354

CLF/MBG

Breast Cancer

309

[***]

21‐L‐011355

CLF/MBG

Breast Cancer

310

[***]

21‐L‐011356

Salvi, Schostok & Pritchard

Lymphoma

311

[***]

21‐L‐011357

CLF/MBG

Breast Cancer

312

[***]

21‐L‐011359

Salvi, Schostok & Pritchard

Breast Cancer

313

[***]

21‐L‐011360

CLF/MBG

Breast Cancer

314

[***]

21‐L‐011361

Salvi, Schostok & Pritchard

Breast Cancer

315

[***]

21‐L‐011363

CLF/MBG

Breast Cancer, Miscarriages

316

[***]

21‐L‐011364

CLF/MBG

Breast Cancer (Paget's Disease)

317

[***]

21‐L‐011368

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma X2

318

[***]

21‐L‐011369

RB/HME

319

[***]

21‐L‐011370

CLF/MBG

Breast Cancer

320

[***]

21‐L‐011371

RB/HME

Breast Cancer

321

[***]

21‐L‐011372

CLF/MBG

Waldenstrom’s Macroglobulinemia

322

[***]

21‐L‐011375

Salvi, Schostok & Pritchard

Breast cancer | 2 Brain Tumors

323

[***]

21‐L‐011376

CLF/MBG

Breast Cancer

324

[***]

21‐L‐011380

Salvi, Schostok & Pritchard

Leukemia, Lymphocytic

325

[***]

21‐L‐011381

CLF/MBG

Breast Cancer, Miscarriage

326

[***]

21‐L‐011384

CLF/MBG

Breast Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

327

[***]

21‐L‐011385

Salvi, Schostok & Pritchard

Stomach cancer

328

[***]

21‐L‐011386

Salvi, Schostok & Pritchard

Breast Cancer x2

329

[***]

21‐L‐011388

CLF/MBG

Breast Cancer, Miscarriages

330

[***]

21‐L‐011389

Salvi, Schostok & Pritchard

Breast cancer & 11 Miscarriages

331

[***]

21‐L‐011391

Salvi, Schostok & Pritchard

Breast Cancer

332

[***]

21‐L‐011392

CLF/MBG

Breast Cancer

333

[***]

21‐L‐011393

RB/HME

Breast Cancer

334

[***]

21‐L‐011395

Salvi, Schostok & Pritchard

Lymphoma, Splenic Marginal Zone B
Cel

335

[***]

21‐L‐011396

Salvi, Schostok & Pritchard

Breast cancer

336

[***]

21‐L‐011397

CLF/MBG

Breast Cancer

337

[***]

21‐L‐011399

RB/HME

Breast Cancer

338

[***]

21‐L‐011401

CLF/MBG

Breast Cancer

339

[***]

21‐L‐011402

Salvi, Schostok & Pritchard

Breast Cancer | Non‐Hodgkin's
Lymphoma

340

[***]

21‐L‐011403

CLF/MBG

Breast Cancer, Miscarriage

341

[***]

21‐L‐011404

CLF/MBG

Breast Cancer

342

[***]

21‐L‐011405

Salvi, Schostok & Pritchard

Breast cancer

343

[***]

21‐L‐011406

Salvi, Schostok & Pritchard

Breast Cancer

344

[***]

21‐L‐011407

CLF/MBG

Hodgkin's Lymphoma

345

[***]

21‐L‐011407

CLF/MBG

Myelodysplastic Syndrome; AML

346

[***]

21‐L‐011409

Salvi, Schostok & Pritchard

Breast cancer

347

[***]

21‐L‐011411

Salvi, Schostok & Pritchard

Breast Cancer

348

[***]

21‐L‐011412

Salvi, Schostok & Pritchard

Breast Cancer ‐ Ductal carcinoma in
situ

349

[***]

21‐L‐011413

CLF/MBG

Breast Cancer

350

[***]

21‐L‐011415

Salvi, Schostok & Pritchard

Breast cancer |

351

[***]

21‐L‐011416

CLF/MBG

Follicular Lymphoma; Diffuse Large B‐
Cell Lymphoma

352

[***]

21‐L‐011417

Salvi, Schostok & Pritchard

Breast Cancer X2

353

[***]

21‐L‐011419

CLF/MBG

Hodgkin's Lymphoma

354

[***]

21‐L‐011421

Salvi, Schostok & Pritchard

Multiple Myeloma

355

[***]

21‐L‐011423

Salvi, Schostok & Pritchard

Non‐Hodgkins Lymphoma

356

[***]

21‐L‐011424

Salvi, Schostok & Pritchard

Breast cancer

357

[***]

21‐L‐011425

CLF/MBG

CML

358

[***]

21‐L‐011426

Salvi, Schostok & Pritchard

Hodgkin's Lymphoma, Nodular
Sclerosis

359

[***]

21‐L‐011429

CLF/MBG

Breast Cancer

360

[***]

21‐L‐011431

Salvi, Schostok & Pritchard

Breast cancer | 3 Miscarriage

361

[***]

21‐L‐011432

RB/HME

Breast Cancer

362

[***]

21‐L‐011433

RB/HME

PCV

363

[***]

21‐L‐011434

CLF/MBG

Breast Cancer

364

[***]

21‐L‐011435

RB/HME

PCV

365

[***]

21‐L‐011436

Salvi, Schostok & Pritchard

Breast Cancer

366

[***]

21‐L‐011437

RB/HME

Breast Cancer

367

[***]

21‐L‐011439

RB/HME

Breast Cancer

368

[***]

21‐L‐011440

CLF/MBG

Breast Cancer

369

[***]

21‐L‐011440

CLF/MBG

CML

370

[***]

21‐L‐011442

RB/HME

Breast Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

371

[***]

21‐L‐011443

Salvi, Schostok & Pritchard

Breast Cancer

372

[***]

21‐L‐011444

Salvi, Schostok & Pritchard

Hodgkin's lymphoma

373

[***]

21‐L‐011445

RB/HME

Breast Cancer

374

[***]

21‐L‐011447

Salvi, Schostok & Pritchard

Breast cancer

375

[***]

21‐L‐011448

RB/HME

NHL

376

[***]

21‐L‐011450

RB/HME

Breast Cancer; Uterine Cancer; Lung
Cancer

377

[***]

21‐L‐011452

RB/HME

Breast Cancer

378

[***]

21‐L‐011453

Salvi, Schostok & Pritchard

Breast Cancer

379

[***]

21‐L‐011454

RB/HME

CML

380

[***]

21‐L‐011455

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma

381

[***]

21‐L‐011456

RB/HME

Breast Cancer

382

[***]

21‐L‐011457

CLF/MBG

Colon Cancer

383

[***]

21‐L‐011458

RB/HME

Breast Cancer

384

[***]

21‐L‐011459

Salvi, Schostok & Pritchard

Breast Cancer

385

[***]

21‐L‐011460

CLF/MBG

Colon Cancer

386

[***]

21‐L‐011461

RB/HME

Breast Cancer

387

[***]

21‐L‐011462

RB/HME

Breast Cancer

388

[***]

21‐L‐011463

CLF/MBG

Breast Cancer

389

[***]

21‐L‐011465

RB/HME

Essential Thrombocythemia

390

[***]

21‐L‐011467

Salvi, Schostok & Pritchard

Leukemia Myelofibrosis

391

[***]

21‐L‐011468

RB/HME

Breast Cancer

392

[***]

21‐L‐011469

RB/HME

AML

393

[***]

21‐L‐011470

RB/HME

CLL

394

[***]

21‐L‐011471

RB/HME

Breast Cancer

395

[***]

21‐L‐011472

RB/HME

Breast Cancer

396

[***]

21‐L‐011473

Salvi, Schostok & Pritchard

Brain Cancer (Ependymoma)

397

[***]

21‐L‐011474

RB/HME

CLL/SLL

398

[***]

21‐L‐011475

Salvi, Schostok & Pritchard

Breast Cancer X2

399

[***]

21‐L‐011476

Salvi, Schostok & Pritchard

Brain Cancer

400

[***]

21‐L‐011477

RB/HME

Breast Cancer

401

[***]

21‐L‐011478

Salvi, Schostok & Pritchard

Breast cancer

402

[***]

21‐L‐011479

RB/HME

Lymphoma

403

[***]

21‐L‐011480

Salvi, Schostok & Pritchard

Brain Tumor

404

[***]

21‐L‐011481

RB/HME

Breast Cancer

405

[***]

21‐L‐011483

Salvi, Schostok & Pritchard

Breast Cancer

406

[***]

21‐L‐011484

Salvi, Schostok & Pritchard

Leukemia, Lymphocytic

407

[***]

21‐L‐011485

Salvi, Schostok & Pritchard

Breast Cancer

408

[***]

21‐L‐011486

Salvi, Schostok & Pritchard

Breast Cancer

409

[***]

21‐L‐011487

Salvi, Schostok & Pritchard

Breast Cancer

410

[***]

21‐L‐011488

Salvi, Schostok & Pritchard

Multiple Myeloma

411

[***]

21‐L‐011490

Salvi, Schostok & Pritchard

Lung Cancer

412

[***]

21‐L‐011492

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma x2

413

[***]

21‐L‐011493

RB/HME

NHL

414

[***]

21‐L‐011494

Salvi, Schostok & Pritchard

Leukemia (Hairy Cell)

415

[***]

21‐L‐011495

Salvi, Schostok & Pritchard

Breast Cancer

416

[***]

21‐L‐011496

RB/HME

Miscarriages

417

[***]

21‐L‐011498

RB/HME

Lung Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

418

[***]

21‐L‐011499

RB/HME

Breast Cancer

419

[***]

21‐L‐011500

Salvi, Schostok & Pritchard

breast cancer

420

[***]

21‐L‐011501

Salvi, Schostok & Pritchard

Lung Cancer

421

[***]

21‐L‐011502

Salvi, Schostok & Pritchard

Non‐Hodgkins Lymphoma

422

[***]

21‐L‐011503

Salvi, Schostok & Pritchard

Breast Cancer

423

[***]

21‐L‐011504

Salvi, Schostok & Pritchard

Leukemia, Lymphocytic, Chronic

424

[***]

21‐L‐011506

Salvi, Schostok & Pritchard

Breast Cancer

425

[***]

21‐L‐011507

Salvi, Schostok & Pritchard

Breast Cancer

426

[***]

21‐L‐011508

Salvi, Schostok & Pritchard

Breast cancer

427

[***]

21‐L‐011509

Salvi, Schostok & Pritchard

Breast Cancer

428

[***]

21‐L‐011510

Salvi, Schostok & Pritchard

Breast cancer

429

[***]

21‐L‐011511

Salvi, Schostok & Pritchard

Breast Cancer

430

[***]

21‐L‐011512

RB/HME

Breast Cancer

431

[***]

21‐L‐011512

RB/HME

Breast Cancer

432

[***]

21‐L‐011512

RB/HME

Kidney Cancer

433

[***]

21‐L‐011513

Salvi, Schostok & Pritchard

Hodgkin's Disease | 2 Miscarriages

434

[***]

21‐L‐011515

Salvi, Schostok & Pritchard

Breast cancer

435

[***]

21‐L‐011516

Salvi, Schostok & Pritchard

Multiple Myeloma

436

[***]

21‐L‐011517

Salvi, Schostok & Pritchard

Breast cancer

437

[***]

21‐L‐011521

RB/HME

Thyroid Cancer

438

[***]

21‐L‐011523

RB/HME

Breast Cancer

439

[***]

21‐L‐011524

RB/HME

Breast Cancer

440

[***]

21‐L‐011528

RB/HME

Miscarriages

441

[***]

21‐L‐011529

RB/HME

Breast Cancer

442

[***]

21‐L‐011530

RB/HME

443

[***]

21‐L‐011531

RB/HME

Breast Cancer

444

[***]

21‐L‐011532

RB/HME

Breast Cancer

445

[***]

21‐L‐011533

RB/HME

Breast Cancer

446

[***]

21‐L‐011534

RB/HME

Breast Cancer

447

[***]

21‐L‐011537

RB/HME

Breast Cancer

448

[***]

21‐L‐011538

RB/HME

449

[***]

21‐L‐011540

RB/HME

CML

450

[***]

21‐L‐011541

Salvi, Schostok & Pritchard

Breast Cancer, Stage IV

451

[***]

21‐L‐011542

Salvi, Schostok & Pritchard

Multiple Myeloma

452

[***]

21‐L‐011544

RB/HME

Breast Cancer

453

[***]

21‐L‐011545

RB/HME

Breast Cancer

454

[***]

21‐L‐011546

Salvi, Schostok & Pritchard

Pancreatic Cancer, Mets. Stage IV

455

[***]

21‐L‐011547

RB/HME

Kidney Cancer

456

[***]

21‐L‐011548

RB/HME

NHL

457

[***]

21‐L‐011549

RB/HME

Breast Cancer

458

[***]

21‐L‐011550

RB/HME

Breast Cancer

459

[***]

21‐L‐011551

Salvi, Schostok & Pritchard

Lung Cancer

460

[***]

21‐L‐011552

RB/HME

CLL

461

[***]

21‐L‐011553

RB/HME

462

[***]

21‐L‐011554

Salvi, Schostok & Pritchard

Breast cancer

463

[***]

21‐L‐011557

RB/HME

CLL

464

[***]

21‐L‐011557

RB/HME

CLL

465

[***]

21‐L‐011558

Salvi, Schostok & Pritchard

Non‐Hodgkins Lymphoma

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

466

[***]

21‐L‐011559

RB/HME

NHL

467

[***]

21‐L‐011560

RB/HME

Breast Cancer

468

[***]

21‐L‐011562

RB/HME

CLL

469

[***]

21‐L‐011563

Salvi, Schostok & Pritchard

Breast cancer

470

[***]

21‐L‐011564

RB/HME

NHL

471

[***]

21‐L‐011565

Salvi, Schostok & Pritchard

Breast cancer

472

[***]

21‐L‐011566

RB/HME

NHL

473

[***]

21‐L‐011567

RB/HME

NHL

474

[***]

21‐L‐011568

RB/HME

Hairy Cell Leukemia

475

[***]

21‐L‐011571

Salvi, Schostok & Pritchard

Breast Cancer | Pancreatic Cancer

476

[***]

21‐L‐011573

Salvi, Schostok & Pritchard

Breast Cancer

477

[***]

21‐L‐011574

RB/HME

Breast Cancer

478

[***]

21‐L‐011575

Salvi, Schostok & Pritchard

Breast Cancer

479

[***]

21‐L‐011576

RB/HME

Breast Cancer

480

[***]

21‐L‐011577

Salvi, Schostok & Pritchard

Leukemia, Chronic Lymphocytic

481

[***]

21‐L‐011578

RB/HME

NHL

482

[***]

21‐L‐011579

RB/HME

CLL

483

[***]

21‐L‐011580

RB/HME

Breast Cancer

484

[***]

21‐L‐011581

RB/HME

NHL

485

[***]

21‐L‐011582

RB/HME

486

[***]

21‐L‐011584

Salvi, Schostok & Pritchard

Breast Cancer | Lung Cancer

487

[***]

21‐L‐011585

RB/HME

Breast Cancer

488

[***]

21‐L‐011586

Salvi, Schostok & Pritchard

Leukemia

489

[***]

21‐L‐011587

RB/HME

Breast Cancer

490

[***]

21‐L‐011588

RB/HME

NHL

491

[***]

21‐L‐011589

Salvi, Schostok & Pritchard

Pancreatic Cancer

492

[***]

21‐L‐011590

RB/HME

Multiple Myeloma

493

[***]

21‐L‐011592

RB/HME

CLL

494

[***]

21‐L‐011593

RB/HME

Breast Cancer

495

[***]

21‐L‐011594

RB/HME

CMML

496

[***]

21‐L‐011596

RB/HME

Breast Cancer

497

[***]

21‐L‐011597

RB/HME

Breast Cancer

498

[***]

21‐L‐011598

RB/HME

NHL

499

[***]

21‐L‐011600

Salvi, Schostok & Pritchard

Lymphoma

500

[***]

21‐L‐011602

RB/HME

Breast Cancer

501

[***]

21‐L‐011603

RB/HME

MM/Leukemia

502

[***]

21‐L‐011604

Salvi, Schostok & Pritchard

Breast Cancer

503

[***]

21‐L‐011605

RB/HME

Breast Cancer

504

[***]

21‐L‐011606

RB/HME

Breast Cancer

505

[***]

21‐L‐011607

Salvi, Schostok & Pritchard

Leukemia

506

[***]

21‐L‐011608

RB/HME

Breast Cancer

507

[***]

21‐L‐011609

Salvi, Schostok & Pritchard

Breast cancer x4

508

[***]

21‐L‐011611

Salvi, Schostok & Pritchard

Breast Cancer

509

[***]

21‐L‐011614

RB/HME

Breast Cancer

510

[***]

21‐L‐011615

Salvi, Schostok & Pritchard

Breast Cancer | Lymphoma

511

[***]

21‐L‐011616

RB/HME

AML

512

[***]

21‐L‐011617

Salvi, Schostok & Pritchard

Pancreatic Cancer

513

[***]

21‐L‐011618

RB/HME

NHL (Waldenstroms)

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

514

[***]

21‐L‐011619

RB/HME

Breast Cancer

515

[***]

21‐L‐011620

Salvi, Schostok & Pritchard

Lung Cancer

516

[***]

21‐L‐011621

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma

517

[***]

21‐L‐011622

RB/HME

NHL

518

[***]

21‐L‐011623

RB/HME

AML

519

[***]

21‐L‐011624

Salvi, Schostok & Pritchard

Leukemia

520

[***]

21‐L‐011625

RB/HME

Miscarriages

521

[***]

21‐L‐011626

Salvi, Schostok & Pritchard

Non Hodgkin's Lymphoma

522

[***]

21‐L‐011627

Salvi, Schostok & Pritchard

Lymphoma

523

[***]

21‐L‐011628

RB/HME

Breast Cancer

524

[***]

21‐L‐011629

RB/HME

525

[***]

21‐L‐011630

RB/HME

Leukemia

526

[***]

21‐L‐011631

Salvi, Schostok & Pritchard

Breast Cancer

527

[***]

21‐L‐011632

RB/HME

Miscarriages

528

[***]

21‐L‐011633

Salvi, Schostok & Pritchard

Brain, Prostate & Lung Cancers

529

[***]

21‐L‐011634

RB/HME

Breast Cancer

530

[***]

21‐L‐011635

RB/HME

Breast Cancer

531

[***]

21‐L‐011636

Salvi, Schostok & Pritchard

Lung Cancer, Non‐Small Cell

532

[***]

21‐L‐011637

RB/HME

Breast Cancer

533

[***]

21‐L‐011638

RB/HME

Hodgkin's Lymphoma; prostate
cancer;lymph node

534

[***]

21‐L‐011639

Salvi, Schostok & Pritchard

Breast Cancer

535

[***]

21‐L‐011640

RB/HME

Breast Cancer

536

[***]

21‐L‐011641

RB/HME

Birth Defect

537

[***]

21‐L‐011641

RB/HME

NHL

538

[***]

21‐L‐011642

Salvi, Schostok & Pritchard

Neuroblastoma

539

[***]

21‐L‐011643

RB/HME

Fertility

540

[***]

21‐L‐011644

RB/HME

CLL

541

[***]

21‐L‐011645

RB/HME

Breast Cancer

542

[***]

21‐L‐011647

RB/HME

Breast Cancer

543

[***]

21‐L‐011648

Salvi, Schostok & Pritchard

Breast Cancer

544

[***]

21‐L‐011649

RB/HME

Birth Defect

545

[***]

21‐L‐011650

RB/HME

Breast Cancer

546

[***]

21‐L‐011651

RB/HME

Breast Cancer

547

[***]

21‐L‐011652

RB/HME

Miscarriages

548

[***]

21‐L‐011653

RB/HME

Miscarriages

549

[***]

21‐L‐011654

RB/HME

Breast Cancer

550

[***]

21‐L‐011655

RB/HME

Breast Cancer

551

[***]

21‐L‐011656

RB/HME

CLL

552

[***]

21‐L‐011656

RB/HME

Hairy Cell Leukemia

553

[***]

21‐L‐011657

Salvi, Schostok & Pritchard

Lung Cancer

554

[***]

21‐L‐011658

RB/HME

Testicular Cancer

555

[***]

21‐L‐011659

RB/HME

Breast Cancer

556

[***]

21‐L‐011660

RB/HME

Breast Cancer

557

[***]

21‐L‐011661

RB/HME

Kidney Cancer

558

[***]

21‐L‐011662

RB/HME

Breast Cancer

559

[***]

21‐L‐011663

RB/HME

Breast Cancer

560

[***]

21‐L‐011664

RB/HME

Miscarriages

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

561

[***]

21‐L‐011666

RB/HME

Miscarriages

562

[***]

21‐L‐011667

RB/HME

Breast Cancer

563

[***]

21‐L‐011668

RB/HME

AML

564

[***]

21‐L‐011669

RB/HME

Leukemia

565

[***]

21‐L‐011671

RB/HME

Breast Cancer

566

[***]

21‐L‐011672

RB/HME

Multiple Myeloma

567

[***]

21‐L‐011673

RB/HME

AML

568

[***]

21‐L‐011674

RB/HME

Breast Cancer

569

[***]

21‐L‐011677

RB/HME

Breast Cancer

570

[***]

21‐L‐011679

Salvi, Schostok & Pritchard

Miscarriage (3)

571

[***]

21‐L‐011682

Salvi, Schostok & Pritchard

Breast Cancer

572

[***]

21‐L‐011683

Salvi, Schostok & Pritchard

Multiple Myeloma

573

[***]

21‐L‐011684

Salvi, Schostok & Pritchard

Multiple Myeloma

574

[***]

21‐L‐011685

Salvi, Schostok & Pritchard

Glioblastoma (Brain Tumor)

575

[***]

21‐L‐011689

Salvi, Schostok & Pritchard

Lung Cancer

576

[***]

21‐L‐011690

RB/HME

Liver Cancer

577

[***]

21‐L‐011693

RB/HME

Pancreatic Cancer

578

[***]

21‐L‐011695

Salvi, Schostok & Pritchard

Breast Cancer

579

[***]

21‐L‐011696

Salvi, Schostok & Pritchard

Lung Cancer

580

[***]

21‐L‐011697

Salvi, Schostok & Pritchard

Lung Cancer & Brain Tumor x2

581

[***]

21‐L‐011698

Salvi, Schostok & Pritchard

Breast Cancer

582

[***]

21‐L‐011699

Salvi, Schostok & Pritchard

Breast Cancer

583

[***]

21‐L‐011700

Salvi, Schostok & Pritchard

Breast Cancer

584

[***]

21‐L‐011701

Salvi, Schostok & Pritchard

Breast Cancer

585

[***]

21‐L‐011702

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma

586

[***]

21‐L‐011703

Salvi, Schostok & Pritchard

Breast Cancer

587

[***]

21‐L‐011705

Salvi, Schostok & Pritchard

Breast, Lymphoma, Non‐Hodgkin's Lymphoma, Spindle Cell & Skin Cancer

588

[***]

21‐L‐011708

Salvi, Schostok & Pritchard

Brain Tumor

589

[***]

21‐L‐011709

Salvi, Schostok & Pritchard

Multiple Myeloma

590

[***]

21‐L‐011710

Salvi, Schostok & Pritchard

Breast Cancer

591

[***]

21‐L‐011711

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma (Follicular)

592

[***]

21‐L‐011712

Salvi, Schostok & Pritchard

Pancreatic Cancer

593

[***]

21‐L‐011713

Salvi, Schostok & Pritchard

Brain Cancer

594

[***]

21‐L‐011717

Salvi, Schostok & Pritchard

Breast Cancer

595

[***]

21‐L‐011721

Salvi, Schostok & Pritchard

Glioblastoma Multiforme

596

[***]

21‐L‐011723

Salvi, Schostok & Pritchard

Leukemia | Breast cancer

597

[***]

21‐L‐011724

Salvi, Schostok & Pritchard

Stomach Cancer

598

[***]

21‐L‐011725

Salvi, Schostok & Pritchard

Breast Cancer

599

[***]

21‐L‐011727

Salvi, Schostok & Pritchard

Hodgkin's Lymphoma

600

[***]

21‐L‐011728

Salvi, Schostok & Pritchard

Glioblastoma

601

[***]

21‐L‐011729

Salvi, Schostok & Pritchard

Breast Cancer

602

[***]

21‐L‐011730

Salvi, Schostok & Pritchard

Breast cancer

603

[***]

21‐L‐011731

Salvi, Schostok & Pritchard

Leukemia, Chronic Lymphatic

604

[***]

21‐L‐011732

Salvi, Schostok & Pritchard

Breast cancer

605

[***]

21‐L‐011733

Salvi, Schostok & Pritchard

Breast Cancer

606

[***]

21‐L‐011734

Salvi, Schostok & Pritchard

Pancreatic Cancer

607

[***]

21‐L‐011735

Salvi, Schostok & Pritchard

Lung cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

608

[***]

21‐L‐011736

Salvi, Schostok & Pritchard

Breast Cancer

609

[***]

21‐L‐011737

Salvi, Schostok & Pritchard

Breast Cancer

610

[***]

21‐L‐011738

Salvi, Schostok & Pritchard

Miscarriages (3)

611

[***]

21‐L‐011739

Salvi, Schostok & Pritchard

Breast Cancer ‐ Invasive ductal
carcinoma

612

[***]

21‐L‐011744

Salvi, Schostok & Pritchard

Breast Cancer

613

[***]

21‐L‐011745

Salvi, Schostok & Pritchard

Breast Cancer

614

[***]

21‐L‐011746

Salvi, Schostok & Pritchard

Lymphoma

615

[***]

21‐L‐011748

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma

616

[***]

21‐L‐011749

Salvi, Schostok & Pritchard

Breast Cancer

617

[***]

21‐L‐011751

Salvi, Schostok & Pritchard

Breast Cancer

618

[***]

21‐L‐011752

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma

619

[***]

21‐L‐011754

Salvi, Schostok & Pritchard

Miscarriages (3)

620

[***]

21‐L‐011755

Salvi, Schostok & Pritchard

Breast Cancer

621

[***]

21‐L‐011756

RB/HME

Miscarriages

622

[***]

21‐L‐011757

Salvi, Schostok & Pritchard

Lung Cancer

623

[***]

21‐L‐011758

Salvi, Schostok & Pritchard

Lung Cancer

624

[***]

21‐L‐011759

RB/HME

Miscarriages

625

[***]

21‐L‐011761

Salvi, Schostok & Pritchard

Lymphoma

626

[***]

21‐L‐011762

Salvi, Schostok & Pritchard

Leukemia

627

[***]

21‐L‐011763

RB/HME

Breast Cancer

628

[***]

21‐L‐011765

Salvi, Schostok & Pritchard

Breast Cancer

629

[***]

21‐L‐011767

RB/HME

Breast Cancer

630

[***]

21‐L‐011769

RB/HME

Leukemia

631

[***]

21‐L‐011770

RB/HME

Breast Cancer

632

[***]

21‐L‐011772

Salvi, Schostok & Pritchard

Breast Cancer

633

[***]

21‐L‐011774

RB/HME

Multiple Myeloma

634

[***]

21‐L‐011775

RB/HME

CLL

635

[***]

21‐L‐011777

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma

636

[***]

21‐L‐011778

RB/HME

Breast Cancer

637

[***]

21‐L‐011779

RB/HME

Miscarriages

638

[***]

21‐L‐011781

RB/HME

Birth Defect

639

[***]

21‐L‐011781

RB/HME

Birth Defect

640

[***]

21‐L‐011784

Salvi, Schostok & Pritchard

Lung Cancer

641

[***]

21‐L‐011785

RB/HME

Stomach Cancer

642

[***]

21‐L‐011786

RB/HME

Miscarriages

643

[***]

21‐L‐011787

Salvi, Schostok & Pritchard

Breast cancer

644

[***]

21‐L‐011788

Salvi, Schostok & Pritchard

Leukemia

645

[***]

21‐L‐011791

RB/HME

Testicular Cancer

646

[***]

21‐L‐011792

RB/HME

Kidney Cancer

647

[***]

21‐L‐011794

Salvi, Schostok & Pritchard

Leukemia, Acute

648

[***]

21‐L‐011795

RB/HME

Lung Cancer

649

[***]

21‐L‐011796

Salvi, Schostok & Pritchard

Lung cancer

650

[***]

21‐L‐011797

RB/HME

Miscarriages

651

[***]

21‐L‐011798

RB/HME

Miscarriages

652

[***]

21‐L‐011799

RB/HME

Breast Cancer

653

[***]

21‐L‐011801

RB/HME

Breast Cancer

654

[***]

21‐L‐011803

RB/HME

Breast Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

655

[***]

21‐L‐011805

RB/HME

NHL

656

[***]

21‐L‐011807

Salvi, Schostok & Pritchard

Lung Cancer (Stage IV)

657

[***]

21‐L‐011810

Salvi, Schostok & Pritchard

Leukemia

658

[***]

21‐L‐011811

RB/HME

Breast Cancer

659

[***]

21‐L‐011812

RB/HME

ALL

660

[***]

21‐L‐011813

Salvi, Schostok & Pritchard

Glioblastoma Multiforme

661

[***]

21‐L‐011814

RB/HME

Breast Cancer

662

[***]

21‐L‐011815

Salvi, Schostok & Pritchard

Stomach cancer

663

[***]

21‐L‐011816

Salvi, Schostok & Pritchard

Breast cancer

664

[***]

21‐L‐011817

RB/HME

Miscarriages

665

[***]

21‐L‐011819

Salvi, Schostok & Pritchard

Breast cancer

666

[***]

21‐L‐011821

Salvi, Schostok & Pritchard

Glioblastoma (brain tumor)

667

[***]

21‐L‐011822

Salvi, Schostok & Pritchard

Lung cancer

668

[***]

21‐L‐011823

RB/HME

Breast Cancer

669

[***]

21‐L‐011823

RB/HME

Breast Cancer

670

[***]

21‐L‐011824

RB/HME

Miscarriages

671

[***]

21‐L‐011825

RB/HME

Breast Cancer

672

[***]

21‐L‐011826

Salvi, Schostok & Pritchard

Pancreatic Cancer, Thyroid Cancer

673

[***]

21‐L‐011827

Salvi, Schostok & Pritchard

Pancreatic & Stage IV Lung Cancers

674

[***]

21‐L‐011829

RB/HME

Miscarriages

675

[***]

21‐L‐011830

RB/HME

Miscarriages

676

[***]

21‐L‐011831

Salvi, Schostok & Pritchard

Breast cancer

677

[***]

21‐L‐011833

RB/HME

Leukemia

678

[***]

21‐L‐011834

RB/HME

Miscarriages

679

[***]

21‐L‐011835

RB/HME

Stomach Cancer

680

[***]

21‐L‐011836

Salvi, Schostok & Pritchard

Hodgkin's Lymphoma, Stage 2

681

[***]

21‐L‐011838

RB/HME

Breast Cancer

682

[***]

21‐L‐011838

RB/HME

Breast Cancer

683

[***]

21‐L‐011839

RB/HME

Breast Cancer

684

[***]

21‐L‐011840

Salvi, Schostok & Pritchard

Leukemia ‐ Chronic Myeloid

685

[***]

21‐L‐011841

Salvi, Schostok & Pritchard

Breast cancer X2

686

[***]

21‐L‐011844

Salvi, Schostok & Pritchard

Lung cancer

687

[***]

21‐L‐011846

Salvi, Schostok & Pritchard

Breast Cancer

688

[***]

21‐L‐011847

Salvi, Schostok & Pritchard

Lung cancer

689

[***]

21‐L‐011849

RB/HME

Breast Cancer

690

[***]

21‐L‐011851

Salvi, Schostok & Pritchard

Lung Cancer, Stage III

691

[***]

21‐L‐011852

RB/HME

Breast Cancer

692

[***]

21‐L‐011853

Salvi, Schostok & Pritchard

Leukemia, Acute myeloid

693

[***]

21‐L‐011855

RB/HME

Stomach Cancer

694

[***]

21‐L‐011856

Salvi, Schostok & Pritchard

Breast Cancer, Stage IV

695

[***]

21‐L‐011857

Salvi, Schostok & Pritchard

Breast Cancer

696

[***]

21‐L‐011858

RB/HME

Breast Cancer

697

[***]

21‐L‐011860

RB/HME

Pancreatic Cancer

698

[***]

21‐L‐011861

RB/HME

Breast Cancer

699

[***]

21‐L‐011862

RB/HME

Miscarriages

700

[***]

21‐L‐011863

Salvi, Schostok & Pritchard

Non‐Hodgkin's Lymphoma

701

[***]

21‐L‐011864

RB/HME

Scleroderma

702

[***]

21‐L‐011865

RB/HME

Breast Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

703

[***]

21‐L‐011865

RB/HME

CLL

704

[***]

21‐L‐011865

RB/HME

CLL

705

[***]

21‐L‐011866

RB/HME

Fertility

706

[***]

21‐L‐011867

RB/HME

Breast Cancer

707

[***]

21‐L‐011868

RB/HME

Esophageal Cancer; Rectal Cancer

708

[***]

21‐L‐011869

Salvi, Schostok & Pritchard

Leukemia, acute myeloid

709

[***]

21‐L‐011870

RB/HME

Breast Cancer

710

[***]

21‐L‐011871

Salvi, Schostok & Pritchard

Brain cancer

711

[***]

21‐L‐011872

RB/HME

Pancreatic Cancer

712

[***]

21‐L‐011873

RB/HME

Breast Cancer

713

[***]

21‐L‐011874

RB/HME

Breast Cancer

714

[***]

21‐L‐011875

RB/HME

Breast Cancer

715

[***]

21‐L‐011876

RB/HME

Follicular Lymphoma

716

[***]

21‐L‐011877

Salvi, Schostok & Pritchard

Prostate Cancer

717

[***]

21‐L‐011881

RB/HME

Miscarriages

718

[***]

21‐L‐011882

RB/HME

Breast Cancer

719

[***]

21‐L‐011883

RB/HME

Stomach Cancer

720

[***]

21‐L‐011885

RB/HME

Stomach Cancer

721

[***]

21‐L‐011886

RB/HME

Breast Cancer

722

[***]

21‐L‐011887

RB/HME

723

[***]

21‐L‐011891

RB/HME

Miscarriages

724

[***]

21‐L‐011894

RB/HME

Breast Cancer

725

[***]

21‐L‐011896

RB/HME

Miscarriages

726

[***]

21‐L‐011898

RB/HME

Breast Cancer

727

[***]

21‐L‐011900

RB/HME

Breast Cancer

728

[***]

21‐L‐011903

RB/HME

Miscarriages

729

[***]

21‐L‐011904

RB/HME

Miscarriages

730

[***]

21‐L‐011908

RB/HME

Breast Cancer

731

[***]

21‐L‐011909

RB/HME

Miscarriages

732

[***]

21‐L‐011911

RB/HME

Breast Cancer

733

[***]

21‐L‐011912

RB/HME

Miscarriages

734

[***]

21‐L‐011913

RB/HME

Miscarriages

735

[***]

21‐L‐011915

RB/HME

Breast Cancer

736

[***]

21‐L‐011916

RB/HME

Birth Defect

737

[***]

21‐L‐011918

RB/HME

Breast Cancer

738

[***]

21‐L‐011919

RB/HME

Birth Defect

739

[***]

21‐L‐011920

RB/HME

NHL

740

[***]

21‐L‐011921

RB/HME

Kidney Cancer

741

[***]

21‐L‐011922

RB/HME

Kidney Cancer

742

[***]

21‐L‐011923

RB/HME

Breast Cancer

743

[***]

21‐L‐011924

RB/HME

Miscarriages

744

[***]

21‐L‐011925

RB/HME

Testicular Cancer

745

[***]

21‐L‐011926

RB/HME

NHL

746

[***]

21‐L‐011927

RB/HME

Miscarriages

747

[***]

21‐L‐011928

RB/HME

MS; MC

748

[***]

21‐L‐011944

RB/HME

Breast Cancer

749

[***]

21‐L‐011959

RB/HME

Pancreatic Cancer

750

[***]

21‐L‐011983

Corboy & Demetrio

Breast Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

751

[***]

21‐L‐011994

Corboy & Demetrio

Breast Cancer

752

[***]

21‐L‐012003

Corboy & Demetrio

Breast cancer ‐ DCIS ductal carcinoma

753

[***]

21‐L‐012006

Corboy & Demetrio

Papillary thyroid cancer

754

[***]

21‐L‐012006

Corboy & Demetrio

Papillary thyroid cancer

755

[***]

21‐L‐012007

Corboy & Demetrio

Birth injury bi‐lateral cleft lip and
palate

756

[***]

21‐L‐012008

Corboy & Demetrio

Polycythemia Vera

757

[***]

21‐L‐012678

Salvi, Schostok & Pritchard

Myeloma

758

[***]

21‐L‐012714

Salvi, Schostok & Pritchard

Breast Cancer

759

[***]

21‐L‐012716

Salvi, Schostok & Pritchard

NHL

760

[***]

21‐L‐012932

RB/HME

AML

761

[***]

21‐L‐012934

RB/HME

Breast Cancer

762

[***]

22‐L‐000298

Salvi, Schostok & Pritchard

ALL

763

[***]

22‐L‐001179

RB/HME

AML

764

[***]

22‐L‐001180

RB/HME

Breast Cancer

765

[***]

22‐L‐001181

RB/HME

NHL

766

[***]

22‐L‐001446

RB/HME

Breast Cancer

767

[***]

22‐L‐001988

CLF/MBG

Myeloma

768

[***]

22‐L‐001996

RB/HME

Multiple Myeloma

769

[***]

22‐L‐002835

RB/HME

Breast Cancer

770

[***]

22‐L‐002842

RB/HME

Breast Cancer

771

[***]

22‐L‐002846

RB/HME

Breast Cancer

772

[***]

22‐L‐002847

RB/HME

Breast Cancer

773

[***]

22‐L‐002852

RB/HME

Breast Cancer

774

[***]

22‐L‐002853

RB/HME

AML

775

[***]

22‐L‐002854

RB/HME

Pancreatic Cancer

776

[***]

22‐L‐002855

RB/HME

Breast Cancer

777

[***]

22‐L‐003036

SSP

Glioblastoma

778

[***]

22‐L‐003042

SSP

Breast Cancer

779

[***]

22‐L‐003044

SSP

Breast Cancer

780

[***]

22‐L‐003046

SSP

MGUS

781

[***]

22‐L‐003177

Breast Cancer

782

[***]

22‐L‐003186

NHL

783

[***]

22‐L‐003187

Breast/NHL

784

[***]

22‐L‐004720

RB/HME

PCV/CLL

785

[***]

22‐L‐004755

RB/HME

Breast Cancer

786

[***]

22‐L‐006970

RB/HME

Kidney Cancer

787

[***]

22‐L‐006973

RB/HME

Breast Cancer

788

[***]

22‐L‐006974

RB/HME

Breast Cancer

789

[***]

22‐L‐006980

RB/HME

Breast Cancer

790

[***]

22‐L‐006982

RB/HME

Breast Cancer

791

[***]

22‐L‐006985

RB/HME

Multiple Myeloma

792

[***]

22‐L‐006989

RB/HME

Breast Cancer

793

[***]

22‐L‐006991

RB/HME

Breast Cancer

794

[***]

22‐L‐006992

RB/HME

Breast Cancer

795

[***]

22‐L‐006993

RB/HME

Breast Cancer

796

[***]

22‐L‐006995

RB/HME

AML

797

[***]

22‐L‐007002

RB/HME

Breast Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

798

[***]

22‐L‐008438

RB/HME

CLL

799

[***]

22‐L‐008445

RB/HME

NHL

800

[***]

22-L-008794

TKK

Breast Cancer

801

[***]

22‐L‐009082

CLF/MBG

Breast Cancer

802

[***]

22‐L‐009098

RB/HME

NHL

803

[***]

22‐L‐009103

RB/HME

Breast Cancer

804

[***]

22‐L‐009110

RB/HME

Breast Cancer

805

[***]

22‐L‐009112

RB/HME

Breast Cancer

806

[***]

22‐L‐009113

RB/HME

Breast Cancer

807

[***]

22‐L‐009115

RB/HME

Breast Cancer

808

[***]

22‐L‐009116

RB/HME

Breast Cancer

809

[***]

22‐L‐009117

RB/HME

Breast Cancer

810

[***]

22‐L‐009118

RB/HME

Breast Cancer

811

[***]

22‐L‐009119

RB/HME

Breast Cancer

812

[***]

22‐L‐009121

RB/HME

Lymphoma

813

[***]

22‐L‐009122

RB/HME

NHL

814

[***]

22‐L‐009183

CLF/MBG

NHL

815

[***]

22‐L‐009193

CLF/MBG

Thyroid Cancer

816

[***]

22‐L‐009345

RB/HME

Breast Cancer

817

[***]

22‐L‐009346

RB/HME

Breast Cancer

818

[***]

22‐L‐009347

RB/HME

Breast Cancer

819

[***]

22‐L‐009348

RB/HME

Leukemia

820

[***]

22‐L‐009356

RB/HME

Breast Cancer

821

[***]

22‐L‐009409

Corboy & Demetrio

Pancreatic Cancer

822

[***]

22-L-009500

TKK

Neuroendocrine Cancer

823

[***]

22-L-009500

TKK

Pancreatic Cancer

824

[***]

22‐L‐009549

RB/HME

Breast Cancer

825

[***]

22‐L‐009552

RB/HME

Breast Cancer

826

[***]

22‐L‐009553

RB/HME

Breast Cancer

827

[***]

22‐L‐009554

RB/HME

AML

828

[***]

22‐L‐009683

CLF/MBG

Colon Cancer

829

[***]

22‐L‐011116

CLF/MBG

Follicular Lymphoma; thyroid cancer;
breast cancer; DLBCL

830

[***]

22‐L‐011144

RB/HME

Breast Cancer

831

[***]

22‐L‐011148

RB/HME

NHL

832

[***]

22‐L‐011164

RB/HME

Hairy Cell Leukemia

833

[***]

22‐L‐011165

RB/HME

Breast Cancer

834

[***]

22‐L‐011211

RB/HME

Myeloma

835

[***]

22-L-011253

TKK

Breast Cancer

836

[***]

22‐L‐011408

KJS

Esophageal Cancer

837

[***]

22‐L‐011409

KJS

Breast Cancer

838

[***]

22‐L‐011410

KJS

Colon Cancer

839

[***]

22‐L‐011428

KJS

Breast Cancer

840

[***]

22‐L‐011479

SSP

PCV

841

[***]

22‐L‐011480

SSP

Breast Cancer

842

[***]

22‐L‐011481

SSP

Neuroendocrine Tumor/GIST

843

[***]

22‐L‐011483

SSP

844

[***]

22‐L‐011485

SSP

Breast Cancer

CLAIMANT NAME(S)

CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

Filed After 1/19

845

[***]

23‐L‐000031

CLF/MBG

Endometrial Cancer

846

[***]

23‐L‐000114

RB/HME

Breast Cancer

847

[***]

23‐L‐000548

RB/HME

Breast Cancer

Yes

Willowbrook: Group Settlement Term Sheet Appendix B

CLAIMANT NAME(S)

NEW CASE NUMBER

FIRM

DIAGNOSIS/DIAGNOSES**

[***]

UNFILED

Smith Lacien

[***]

UNFILED

Smith Lacien

Breast Cancer

[***]

UNFILED

Smith Lacien

Breast Cancer

[***]

UNFILED

Smith Lacien

Multiple Myeloma

[***]

UNFILED

Cavanagh Law Group

Lymphoma

[***]

UNFILED

RB/HME

Breast Cancer

[***]

UNFILED

SSP

Glioblastoma

[***]

UNFILED

SSP

NHL

[***]

UNFILED

SSP

Breast Cancer

[***]

UNFILED

SSP

Lung Cancer

[***]

UNFILED

Myeloproliferative Neoplasm

[***]

UNFILED

Stomach Cancer

[***]

UNFILED

Breast Cancer

[***]

UNFILED

CLL

[***]

UNFILED

Breast Cancer

[***]

UNFILED

Breast Cancer

[***]

UNFILED

Breast Cancer

[***]

UNFILED

Breast Cancer

[***]

UNFILED

Breast Cancer

[***]

UNFILED

WSOR

Breast Cancer

[***]

UNFILED

WSOR

Breast Cancer

[***]

UNFILED

KJS

Uterine Cancer

[***]

UNFILED

Colon Cancer

[***]

UNFILED

NHL

[***]

UNFILED

SSP

Malt Lymphoma

[***]

UNFILED

Brain Cancer

[***]

UNFILED

Breast Cancer

Willowbrook: Group Settlement Term Sheet Appendix C


CLAIMANT NAME(S)	CASE NUMBER	FIRM	DIAGNOSIS/DIAGNOSES
Susan Kamuda	18‐L‐010475	Salvi, Schostok & Pritchard	Breast Cancer
Brian Kamuda	18‐L‐010475	Salvi, Schostok & Pritchard	Follicular Lymphoma; Diffuse Large B‐Cell Lymphoma
Teresa Fornek	18‐L‐010744	Smith Lacien	ALL
Doug Fornek	N/A	Smith Lacien
Heather Schumacher and Michael Schumacher	18‐L‐011939	RB/HME	Hodgkin's Lymphoma

Willowbrook: Group Settlement Term Sheet Appendix D


			LAW FIRM NAME
1			BARNEY & KARAMANIS
2			CAVANAGH LAW GROUP
3			THE COLLINS LAW FIRM
4			CLIFFORD LAW OFFICES
5			CORBOY & DEMETRIO
6			DOLAN LAW
7			EDELSON P.C.
8			GOLDBERG WEISMAN & CAIRO
9			HART MCLAUGHLIN & ELDRIDGE
10			KRALOVEC JAMBOIS & SCHWARTZ
11			MCNABOLA LAW GROUP
12			MINER BARNHILL & GALLAND
13			MOTHERWAY & NAPLETON
14			NOLAN LAW GROUP
15			POWER ROGERS
16			ROMANUCCI & BLANDIN
17			SALVI SCHOSTOK & PRITCHARD
18			SMITH LACIEN
19			TAXMAN POLLACK MURRAY & BEKKERMAN
20			TOMASIK KOTIN KASSERMAN
21			WINTERS SALZETTA O'BRIEN & RICHARDSON
22			WISE MORRISSEY

Willowbrook: Group Settlement Term Sheet Appendix E

INSTRUCTIONS: If your response to any question in this Settlement Plaintiff Fact Sheet exceeds the space limitation provided in these fillable PDF forms, you must attach additional pages labeling said pages as an Attachment to the respective document and identify the question to which the additional information applies to.

IN THE CIRCUIT COURT OF COOK COUNTY, ILLINOIS COUNTY DEPARTMENT, LAW DIVISION


IN RE: WILLOWBROOK ETHYLENE OXIDE LITIGATION			Consolidated for Pretrial and Discovery Purposes Under No. 18 L 10475

APPENDIX E

SETTLEMENT PLAINTIFF FACT SHEET

This Settlement Plaintiff Fact Sheet must be completed by or on behalf of each Opt- Out, as defined in the Willowbrook Group Binding Term Sheet (“Term Sheet”)1. Please answer every question to the best of your knowledge. In completing this Settlement Plaintiff Fact Sheet, you are under oath and must provide information that is true and correct to the best of your knowledge as if answering under Illinois law. If you cannot recall all details requested, please provide as much information as you can. Please do not leave any questions unanswered or blank, and attach additional pages if you need more space to answer any of the questions associated with this Settlement Plaintiff Fact Sheet.

Information provided will only be used for purposes related to settlement evaluation and may be disclosed only as permitted by the Stipulation and Order Governing the Protection and Exchange of Confidential Information in the litigation.2

______________________________________

1 “Opt-Out” means an Eligible Claimant who has declined to accept his or her settlement allocation or the terms of the Release, as described in the Term Sheet.

2 In the event the Opt Out chooses to continue to litigate his or her case, the submission of this Settlement Plaintiff Fact Sheet does not satisfy or discharge his or her obligation to prepare a Plaintiff Fact Sheet for the litigation as

required under court orders or discovery rules.

I.CASE INFORMATION

1.Name of person on whose behalf this Settlement Plaintiff Fact Sheet is being prepared (first, middle, last):

2.Name of person completing this form:

3.Please state the following for the civil action filed by the Opt-Out, if any:

a.Case caption:

b.Docket number:

c.Contact information of principal attorney representing the Opt-Out:

Name:

Firm:

Address:

Telephone Number:

Fax Number:

E-mail Address:

4.If you are completing this document in a derivative capacity (e.g., you filed a loss of consortium claim derived from injuries suffered by a family member), please provide the name of the allegedly injured family member(s):

5.If you are completing this document in a representative capacity (e.g., as a legal guardian, or on behalf of the estate of a deceased person), please complete the following:

a.Your name, including other names you have used or by which you have been known and dates you used those names:

b.Current address

c.In what capacity you are representing the individual or estate:

d.If you were appointed as a representative by a court, state the: Court that appointed you_____________________; Date of appointment______________________

e.What is your relationship to the individual you represent:

f.If you represent a decedent’s estate, please state the date and cause of decedent’s death:

II.PERSONAL INFORMATION

1.Opt-Out’s Name:

Other names by which Opt-Out has been known (from prior marriages or otherwise, if any):

2.Sex:

3.Race:

4.Social Security Number:

5.Driver’s license number and state issuing license (if you have had driver’s licenses

6.in more than one state, list response for each state):

7.Date and Place of Birth (City, State, Country):

“YOU” AND “YOUR” REFERENCED IN SECTIONS III-VI OF THIS PLAINTIFF FACT SHEET REQUEST INFORMATION ABOUT THE OPT-OUT, OR, IF THE OPT OUT IS SOMEONE BRINGING A CLAIM IN A REPRESENTATIVE OR DERIVATIVE CAPACITY, THE PERSON ALLEGEDLY INJURED BY ETHYLENE OXIDE FROM WHOM THE CLAIM DERIVES, UNLESS OTHERWISE SPECIFIED.3

III.CLAIM INFORMATION

1.Have YOU suffered any physical injuries or illness as a result of YOUR alleged ethylene oxide exposure from the Willowbrook facility as described in III below?

Yes ☐ No ☐

If yes, please describe in detail the following:

a.The diagnosis or illness claimed and when any corresponding symptoms first began.

Special instructions: Please describe the nature and extent of the claimed diagnosis or injury with specificity. For example, for a cancer-related injury, it is important to write down the type and stage of cancer claimed. Similarly, if a miscarriage-related injury is claimed, please specify the number and type of miscarriage to the extent known.

_________________________________________

3 For example, if the Opt-Out is someone who has asserted a loss of consortium claim derived from injuries suffered by his spouse, Sections II-VI should contain information relating to the allegedly injured spouse.

b.When did YOU first receive a diagnosis, if any, of the injuries or illnesses or occurrences identified in II(1)(a) above? Please insert the month, day (if available), and year (MM/DD/YYYY) of diagnosis for each injury or illness claimed.

c.If YOU claim to have experienced symptoms prior date of diagnosis in part II(1)(a) above, please describe the symptoms and their dates of onset.

IV.EXPOSURE HISTORY

1. Identify any and all residences, places of employment, schools, or other locations where YOU were allegedly exposed to ethylene oxide from the Willowbrook facility, by name to the extent applicable (i.e., business or school), address, and dates of exposure (i.e., MM/DD/YYYY-MM/DD/YYYY).

V.CURRENT MEDICAL CONDITION(S)

1.Do YOU currently suffer from any physical injuries, illnesses or disabilities other than those alleged to be the result of the Willowbrook facility’s ethylene oxide emissions identified in II(1)(a) above?

Yes ☐ No ☐

2.If yes, please list each injury(ies), illness, or disability:

VI.MEDICAL HISTORY

1.Please describe any other medical symptoms or conditions that YOU have experienced or been diagnosed with during the last 15 years, besides those alleged to be attributable to ethylene oxide exposure in Part II above. For each symptom or condition listed, please indicate the approximate date of onset and diagnosis.

VII.LOSS OF CONSORTIUM

1.Are you a Plaintiff who claims loss of consortium based on a family member who was allegedly injured by ethylene oxide exposure?

Yes ☐ No ☐

2.If yes, please describe each injury(ies), illness, or disability you claim to have suffered:

VIII.DECEASED INDIVIDUALS

1.Are you a Plaintiff and/or legal representative filling this out on behalf of an individual who is deceased?

Yes ☐ No ☐

If yes, please attach a copy of the Death Certificate and a copy of the letter of administration:

a Date of Death

b. Place of death (city, state and country)

IX.VERIFICATION

Under the penalties as provided by law pursuant to Section 1 -109 of the Illinois Code of Civil Procedure, the undersigned certifies that the statements set forth in this Plaintiff Fact Sheet are true and correct. This certification shall have the same effect as a verification provided and sworn under oath.

Date: __________________________

Signature_____________________________

Print Name____________________________

Willowbrook: Group Settlement Term Sheet Appendix F

INSTRUCTIONS: If your response to any question in the Mental Health Care Addendum exceeds the space limitation provided in these fillable PDF forms, you must attach additional pages labeling said pages as an Attachment to the respective document and identify the question to which the additional information applies to.

IN THE CIRCUIT COURT OF COOK COUNTY,

ILLINOIS COUNTY DEPARTMENT, LAW DIVISION


IN RE: WILLOWBROOK ETHYLENE OXIDE LITIGATION			Consolidated for Pretrial and Discovery Purposes Under No. 18 L 10475

Appendix F

MENTAL HEALTH CARE ADDENDUM TO PLAINTIFF FACT SHEET

This Mental Health Care Addendum (“Addendum”) must be completed by or on behalf of each Opt-Out, as defined in the Term Sheet, who has claimed on the Settlement Plaintiff Fact Sheet any psychological or psychiatric injury as a consequence of the Opt-Out’s alleged ethylene oxide exposure from the Willowbrook facility. The terms “psychological or psychiatric injury” and “psychological or psychiatric condition” include but are not limited to depressive disorders, anxiety disorders, and/or trauma- and stressor-related psychological or psychiatric disorders.

The terms YOU and YOUR below refer to the Opt Out, or, if the Opt Out is someone bringing a claim in a representative or derivative capacity, the person allegedly injured by ethylene oxide and from whom the claim derives.

I.CASE INFORMATION

1.Name of person on whose behalf this Addendum is being prepared (first, middle, last):

2.Name of person completing this form:

II.PSYCHOLOGICAL AND/OR PSYCHIATRIC INJURY(IES)

1.Please describe in detail the following:

a. Any psychological or psychiatric injury(ies) YOU claim are the consequence of YOUR alleged ethylene oxide exposure from the Willowbrook facility, date of onset of symptoms, and date of diagnosis.

b. Are the injuries identified in II(1)(a) above continuing?

Yes ☐ No ☐

If yes, please identify which injuries.

c. Did YOU ever suffer this injury(ies) prior to the dates set forth in the answer to II(1)(a) above?

Yes ☐ No ☐

If yes, when did YOU suffer the injury(ies) previously?

III.CURRENT PSYCHOLOGICAL OR PSYCHIATRIC CONDITIONS

1.Do YOU currently suffer from any diagnosed psychological or psychiatric conditions other than those that are the result of the Willowbrook facility’s ethylene oxide emissions identified in II(a)?

Yes ☐ No ☐

If yes, please state the following for each condition:

2.Identify the condition(s); their symptoms; date of onset; and date of diagnosis.

IV.MENTAL HEALTH HISTORY

1. Please describe any psychological or psychiatric conditions that YOU have previously experienced or been diagnosed with during the last 15 years, besides those alleged to be attributable to ethylene oxide exposure in Part II above. For each condition listed, please indicate the date of onset and diagnosis.

V.VERIFICATION

Under the penalties as provided by law pursuant to Section 1 -109 of the Illinois Code of Civil Procedure, the undersigned certifies that the statements set forth in this Addendum are true and correct. This certification shall have the same effect as a verification provided and sworn under oath.

Date: __________________________

Signature_____________________________

Print Name____________________________

Willowbrook: Group Settlement Term Sheet Appendix G


Case Name	Member Case Name	Plaintiff
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	Harrell v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	Adams, et al. v. Sterigenics, U.S., LLC, et al.	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	Goodrich v. Sterigenics [Stayed]	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	Horn v. Sterigenics	[***]
In re Sterigenics EtO Georgia	Horn v. Sterigenics	[***]
In re Sterigenics EtO Georgia	Horn v. Sterigenics	[***]
In re Sterigenics EtO Georgia	Horn v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	DiCorpo v. Sterigenics	[***]
In re Sterigenics EtO Georgia	Horn v. Sterigenics	[***]
In re Sterigenics EtO Georgia		[***]
Total Count	31